

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/Caplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/Caplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/Caplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/Caplus enhanced with utility model patents from China
NEWS 27 JUL 16 Caplus enhanced with French and German abstracts
NEWS 28 JUL 18 CA/Caplus patent coverage enhanced
NEWS 29 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 30 JUL 30 USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 00:08:48 ON 03 AUG 2007

=> file medline
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 00:09:21 ON 03 AUG 2007

FILE LAST UPDATED: 2 Aug 2007 (20070802/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s statin?

L1 10934 STATIN?

=> s glucose metabol?

300457 GLUCOSE

3212577 METABOL?

L2 16662 GLUCOSE METABOL?
(GLUCOSE(W)METABOL?)

=> s l1 and l2

L3 22 L1 AND L2

=> d 1-22

L3 ANSWER 1 OF 22 MEDLINE on STN

Full Text

AN 2007321380 MEDLINE

DN PubMed ID: 17533580

TI Effect of telmisartan on cholesterol levels in patients with hypertension
- Saga Telmisartan Aggressive Research (STAR).

AU Inoue T; Morooka T; Moroe K; Ikeda H; Node K

CS Department of Cardiovascular and Renal Medicine, Saga University Faculty
of Medicine, Saga, Japan.. inouete@med.saga-u.ac.jp

SO Hormone and metabolic research. Hormon- und Stoffwechselforschung.

Hormones et métabolisme, (2007 May) Vol. 39, No. 5, pp. 372-6.

Journal code: 0177722. ISSN: 0018-5043.

CY Germany: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

(CLINICAL TRIAL)

LA English

FS Priority Journals

EM 200707

ED Entered STN: 30 May 2007

Last Updated on STN: 4 Jul 2007

Entered Medline: 3 Jul 2007

L3 ANSWER 2 OF 22 MEDLINE on STN

Full Text

AN 2007253287 MEDLINE

DN PubMed ID: 17462167

TI Screening for type 2 diabetes: literature review and economic modelling.

AU Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams
R; John A

CS Department of Public Health, University of Aberdeen, UK.

SO Health technology assessment (Winchester, England), (2007 May) Vol. 11,

No. 17, pp. iii-iv, ix-xi, 1-125. Ref: 268

Journal code: 9706284. ISSN: 1366-5278.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 200707

ED Entered STN: 28 Apr 2007

Last Updated on STN: 1 Aug 2007

Entered Medline: 31 Jul 2007

L3 ANSWER 3 OF 22 MEDLINE on STN

Full Text

AN 2006590592 MEDLINE

DN PubMed ID: 17002798

TI Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes:
therapeutic options beyond statins.

AU Tenenbaum Alexander; Fisman Enrique Z; Motro Michael; Adler Yehuda

CS Cardiac Rehabilitation Institute, the Chaim Sheba Medical Center, 52621

Tel-Hashomer, Israel.. altenen@post.tau.ac.il

SO Cardiovascular diabetology, (2006) Vol. 5, pp. 20. Electronic

Publication: 2006-09-26. Ref: 78

Journal code: 101147637. E-ISSN: 1475-2840.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
General Review; (REVIEW)

LA English

FS Priority Journals

EM 200611

ED Entered STN: 6 Oct 2006
Last Updated on STN: 15 Nov 2006
Entered Medline: 14 Nov 2006

L3 ANSWER 4 OF 22 MEDLINE on STN

Full Text

AN 2006413066 MEDLINE

DN PubMed ID: 16835466

TI **Statins: beneficial or adverse for glucose metabolism.**

AU Sasaki Jun; Iwashita Mikio; Kono Suminori

CS Graduate School of Clinical Trial Management, International University of Health and Welfare, Fukuoka, Japan.. jsas@nifty.com

SO Journal of atherosclerosis and thrombosis, (2006 Jun) Vol. 13, No. 3, pp. 123-9. Ref: 37
Journal code: 9506298. ISSN: 1340-3478.

CY Japan

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA English

FS Priority Journals

EM 200609

ED Entered STN: 13 Jul 2006
Last Updated on STN: 29 Sep 2006
Entered Medline: 28 Sep 2006

L3 ANSWER 5 OF 22 MEDLINE on STN

Full Text

AN 2006407807 MEDLINE

DN PubMed ID: 16685502

TI Effects of **statins** on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.

AU Nakata M; Nagasaka S; Kusaka I; Matsuo H; Ishibashi S; Yada T

CS Department of Physiology, Division of Integrative Physiology, Jichi Medical University, School of Medicine, Shimotsuke, Tochigi 329-0498, Japan.

SO Diabetologia, (2006 Aug) Vol. 49, No. 8, pp. 1881-92. Electronic Publication: 2006-05-10.
Journal code: 0006777. ISSN: 0012-186X.

CY Germany: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 200610

ED Entered STN: 11 Jul 2006
Last Updated on STN: 25 Oct 2006
Entered Medline: 24 Oct 2006

L3 ANSWER 6 OF 22 MEDLINE on STN

Full Text

AN 2006369228 MEDLINE

DN PubMed ID: 16784923

TI Effect of atorvastatin (10 mg/day) on **glucose metabolism** in patients with the metabolic syndrome.

AU Huptas Sebastian; Geiss Hans-Christian; Otto Carsten; Parhofer Klaus Georg

CS Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.

SO The American journal of cardiology, (2006 Jul 1) Vol. 98, No. 1, pp. 66-9. Electronic Publication: 2006-05-04.
Journal code: 0207277. ISSN: 0002-9149.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(CLINICAL TRIAL)

LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200608
 ED Entered STN: 21 Jun 2006
 Last Updated on STN: 4 Aug 2006
 Entered Medline: 3 Aug 2006

L3 ANSWER 7 OF 22 MEDLINE on STN
Full Text
 AN 2006207624 MEDLINE
 DN PubMed ID: 16613757
 TI Recent advances in the relationship between obesity, inflammation, and insulin resistance.
 AU Bastard Jean-Philippe; Maachi Mustapha; Lagathu Claire; Kim Min Ji; Caron Martine; Vidal Hubert; Capeau Jacqueline; Feve Bruno
 CS Inserm U680, Faculte de Medecine Pierre et Marie Curie, site Saint-Antoine, Universite Pierre et Marie Curie, Paris 6 et Service de Biochimie et Hormonologie, Hopital Tenon, AP-HP, 75970 Paris cedex 20, France.. jean-philippe.bastard@tnn.ap-hop-paris.fr
 SO European cytokine network, (2006 Mar) Vol. 17, No. 1, pp. 4-12. Ref: 94
 Journal code: 9100879. ISSN: 1148-5493.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200607
 ED Entered STN: 15 Apr 2006
 Last Updated on STN: 21 Jul 2006
 Entered Medline: 20 Jul 2006

L3 ANSWER 8 OF 22 MEDLINE on STN
Full Text
 AN 2006097110 MEDLINE
 DN PubMed ID: 16484739
 TI Effect of pravastatin and atorvastatin on **glucose metabolism** in nondiabetic patients with hypercholesterolemia.
 AU Ishikawa Michiro; Namiki Atsushi; Kubota Tetsuya; Yajima Suguru; Fukazawa Masayuki; Moroi Masao; Sugi Kaoru
 CS Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo.
 SO Internal medicine (Tokyo, Japan), (2006) Vol. 45, No. 2, pp. 51-5.
 Electronic Publication: 2006-02-15.
 Journal code: 9204241. E-ISSN: 1349-7235.
 CY Japan
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200607
 ED Entered STN: 18 Feb 2006
 Last Updated on STN: 11 Jul 2006
 Entered Medline: 10 Jul 2006

L3 ANSWER 9 OF 22 MEDLINE on STN
Full Text
 AN 2005623888 MEDLINE
 DN PubMed ID: 16305524
 TI Cardiorenal consequences of atherosclerosis and **statins** therapy: from the past to the future.
 AU Buemi Michele; Aloisi Carmela; Fulvio Floccari; Caccamo Chiara; Cavallaro Emanuela; Crasci Eleonora; Criseo Manila; Corica Francesco; Frisina Nicola
 CS Chair of Nephrology, Department of Internal Medicine, Messina, Italy.. buemim@Unime.it
 SO Current pharmaceutical design, (2005) Vol. 11, No. 30, pp. 3973-84. Ref: 158
 Journal code: 9602487. ISSN: 1381-6128.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English

FS Priority Journals
 EM 200512
 ED Entered STN: 25 Nov 2005
 Last Updated on STN: 20 Dec 2005
 Entered Medline: 15 Dec 2005

L3 ANSWER 10 OF 22 MEDLINE on STN
Full Text
 AN 2005378765 MEDLINE
 DN PubMed ID: 16009343
 TI **Statins** and transcriptional regulation: the FXR connection.
 AU Habeos Ioannis; Ziros Panos G; Psyrogiannis Agathoklis; Vagenakis Apostolos G; Papavassiliou Athanasios G
 CS Department of Biochemistry, School of Medicine, University of Patras, 26110 Patras, Greece.
 SO Biochemical and biophysical research communications, (2005 Aug 26) Vol. 334, No. 2, pp. 601-5.
 Journal code: 0372516. ISSN: 0006-291X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200509
 ED Entered STN: 23 Jul 2005
 Last Updated on STN: 27 Sep 2005
 Entered Medline: 26 Sep 2005

L3 ANSWER 11 OF 22 MEDLINE on STN
Full Text
 AN 2005305974 MEDLINE
 DN PubMed ID: 15953504
 TI Cardiovascular risk: prevention and treatment of the metabolic syndrome.
 AU Tuomilehto Jaakko
 CS University of Helsinki and National Public Health Institute, Mannerheimintie 166, Helsinki FIN-00300, Finland..
jaakko.tuomilehto@ktl.fi
 SO Diabetes research and clinical practice, (2005 Jun) Vol. 68 Suppl 2, pp. S28-35. Electronic Publication: 2005-04-15. Ref: 30
 Journal code: 8508335. ISSN: 0168-8227.
 CY Ireland
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200510
 ED Entered STN: 15 Jun 2005
 Last Updated on STN: 6 Oct 2005
 Entered Medline: 5 Oct 2005

L3 ANSWER 12 OF 22 MEDLINE on STN
Full Text
 AN 2005231997 MEDLINE
 DN PubMed ID: 15866088
 TI **Statins** have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
 AU Tanriverdi Hamit Alper; Barut Aykut; Sarikaya Selda
 CS Menopause Clinic, Department of Obstetrics and Gynecology, Karaelmas University Medical School, 67600 Kozlu, Zonguldak, Turkey..
tanriverdi@artemisonline.net
 SO European journal of obstetrics, gynecology, and reproductive biology, (2005 May 1) Vol. 120, No. 1, pp. 63-8.
 Journal code: 0375672. ISSN: 0301-2115.
 CY Ireland
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200509
 ED Entered STN: 4 May 2005
 Last Updated on STN: 13 Sep 2005

Entered Medline: 12 Sep 2005

L3 ANSWER 13 OF 22 MEDLINE on STN

Full Text

AN 2005078286 MEDLINE
DN PubMed ID: 15707267
TI Metabolic syndrome and risk of stroke.
AU Brown William Virgil
CS Charles Howard Candler Professor of Medicine, Emory University School of Medicine, Decatur, Georgia, USA.
SO Clinical cornerstone, (2004) Vol. 6 Suppl 3, pp. S30-4. Ref: 28
Journal code: 9816002. ISSN: 1098-3597.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200505
ED Entered STN: 16 Feb 2005
Last Updated on STN: 4 May 2005
Entered Medline: 3 May 2005

L3 ANSWER 14 OF 22 MEDLINE on STN

Full Text

AN 2005016559 MEDLINE
DN PubMed ID: 15642080
TI Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
AU Gaudiani L M; Lewin A; Meneghini L; Perevozskaya I; Plotkin D; Mitchel Y; Shah S
CS Marin Endocrine Associates, Greenbrae, CA 94904, USA.. lmqmd@earthlink.net
SO Diabetes, obesity & metabolism, (2005 Jan) Vol. 7, No. 1, pp. 88-97.
Journal code: 100883645. ISSN: 1462-8902.
CY England: United Kingdom
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200504
ED Entered STN: 12 Jan 2005
Last Updated on STN: 13 Apr 2005
Entered Medline: 12 Apr 2005

L3 ANSWER 15 OF 22 MEDLINE on STN

Full Text

AN 2005013802 MEDLINE
DN PubMed ID: 15386813
TI Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage.
AU Raz Itamar; Eldor Roi; Cernea Simona; Shafrir Eleazar
CS Department of Medicine, Diabetes Center, Hadassah University Hospital, Jerusalem 91120, Israel.. ntv502@netvision.net.il
SO Diabetes/metabolism research and reviews, (2005 Jan-Feb) Vol. 21, No. 1, pp. 3-14. Ref: 133
Journal code: 100883450. ISSN: 1520-7552.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200505
ED Entered STN: 11 Jan 2005
Last Updated on STN: 27 May 2005
Entered Medline: 26 May 2005

L3 ANSWER 16 OF 22 MEDLINE on STN

Full Text

AN 2004236864 MEDLINE

DN PubMed ID: 15123532
 TI Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
 AU Tenenbaum Alexander; Motro Michael; Fisman Enrique Z; Schwammenthal Ehud; Adler Yehuda; Goldenberg Ilan; Leor Jonathan; Boyko Valentina; Mandelzweig Lori; Behar Solomon
 CS Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel-Hashomer, 52621 Israel.. altenen@post.tau.ac.il
 SO Circulation, (2004 May 11) Vol. 109, No. 18, pp. 2197-202. Electronic Publication: 2004-05-03.
 Journal code: 0147763. E-ISSN: 1524-4539.
 CY United States
 DT (CLINICAL TRIAL)
 (CONTROLLED CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200410
 ED Entered STN: 12 May 2004
 Last Updated on STN: 8 Oct 2004
 Entered Medline: 7 Oct 2004

L3 ANSWER 17 OF 22 MEDLINE on STN

Full Text

AN 2002302311 MEDLINE
 DN PubMed ID: 12043065
 TI [Disorders of lipid and glucose metabolism. Long-term adverse effects of antiretroviral therapy].
 Störungen des Lipid- und Glukosestoffwechsels. Langzeitnebenwirkungen antiretroviraler Therapie.
 AU Landauer N; Goebel F D
 CS Poliklinik, Klinikum Innenstadt der LMU Munchen.
 SO MMW Fortschritte der Medizin, (2002 Apr 9) Vol. 144 Suppl 1, pp. 16-8.
 Journal code: 100893959. ISSN: 1438-3276.
 CY Germany: Germany, Federal Republic of
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200208
 ED Entered STN: 5 Jun 2002
 Last Updated on STN: 29 Aug 2002
 Entered Medline: 28 Aug 2002

L3 ANSWER 18 OF 22 MEDLINE on STN

Full Text

AN 2002177718 MEDLINE
 DN PubMed ID: 11910982
 TI [Metabolic considerations in the treatment of coronary disease in diabetic patients].
 Approche metabolique du traitement de la maladie coronaire chez le patient diabetique.
 AU Piot C
 CS Service de Cardiologie B, Hopital A. de Villeneuve, CHU de Montpellier, 371, avenue du Doyen G. Giraud, 34295 Montpellier.. c-piot@chu-montpellier.fr
 SO Diabetes & metabolism, (2001 Nov) Vol. 27, No. 5 Pt 2, pp. S25-9. Ref: 21
 Journal code: 9607599. ISSN: 1262-3636.
 CY France
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA French
 FS Priority Journals
 EM 200205
 ED Entered STN: 26 Mar 2002
 Last Updated on STN: 3 May 2002
 Entered Medline: 2 May 2002

L3 ANSWER 19 OF 22 MEDLINE on STN

Full Text

AN 2001527036 MEDLINE
 DN PubMed ID: 11560458
 TI Hypertriglyceridemic hyperapob: the unappreciated atherogenic
 dyslipoproteinemia in type 2 diabetes mellitus.
 AU Sniderman A D; Scantlebury T; Cianflone K
 CS Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7.22, McGill
 University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West,
 Montreal, Quebec H3A 1A1, Canada.
 SO Annals of internal medicine, (2001 Sep 18) Vol. 135, No. 6, pp. 447-59.
 Ref: 144
 Journal code: 0372351. ISSN: 0003-4819.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200110
 ED Entered STN: 1 Oct 2001
 Last Updated on STN: 8 Oct 2001
 Entered Medline: 4 Oct 2001

L3 ANSWER 20 OF 22 MEDLINE on STN

Full Text

AN 2001087532 MEDLINE
 DN PubMed ID: 11142470
 TI Attenuating cardiovascular risk factors in patients with type 2 diabetes.
 AU Garber A J
 CS Baylor College of Medicine, Houston, Texas, USA.
 SO American family physician, (2000 Dec 15) Vol. 62, No. 12, pp. 2633-42,
 2645-6. Ref: 38
 Journal code: 1272646. ISSN: 0002-838X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200101
 ED Entered STN: 22 Mar 2001
 Last Updated on STN: 22 Mar 2001
 Entered Medline: 18 Jan 2001

L3 ANSWER 21 OF 22 MEDLINE on STN

Full Text

AN 2001020593 MEDLINE
 DN PubMed ID: 10955016
 TI [Weight reduction, **statins** or fibrates? How to reach lipid goal values
 in diabetic patients].
 Abspecken, **Statine** oder Fibrate? Wie Sie bei Diabetikern die
 Lipid-Zielwerte erreichen.
 AU Sailer D
 CS Diabeteszentrum Bad Neustadt/Saale.. dietmar.sailer@dgn.de
 SO MMW Fortschritte der Medizin, (2000 Jul 27) Vol. 142, No. 30, pp. 30-2.
 Journal code: 100893959. ISSN: 1438-3276.
 CY GERMANY: Germany, Federal Republic of
 DT (COMPARATIVE STUDY)
 (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200011
 ED Entered STN: 22 Mar 2001
 Last Updated on STN: 22 Mar 2001
 Entered Medline: 7 Nov 2000

L3 ANSWER 22 OF 22 MEDLINE on STN

Full Text

AN 1998288843 MEDLINE
 DN PubMed ID: 9627154
 TI Pharmacological treatment of diabetic patients with cardiovascular
 complications.
 AU Sawicki P T; Berger M

CS Department of Metabolic Diseases and Nutrition, Heinrich-Heine University
of Dusseldorf, WHO Collaborating Centre for Diabetes, Germany.
SO Journal of internal medicine, (1998 Mar) Vol. 243, No. 3, pp. 181-9. Ref:
68
Journal code: 8904841. ISSN: 0954-6820.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 199806
ED Entered STN: 13 Jul 1998
Last Updated on STN: 13 Jul 1998
Entered Medline: 26 Jun 1998

=> s (HMG-CoA reduct?)
9469 HMG
35097 COA
615156 REDUCT?
L4 4954 (HMG-COA REDUCT?)
(HMG(W) COA(W) REDUCT?)

=> d his

(FILE 'HOME' ENTERED AT 00:08:48 ON 03 AUG 2007)

FILE 'MEDLINE' ENTERED AT 00:09:21 ON 03 AUG 2007

L1 10934 S STATIN?
L2 16662 S GLUCOSE METABOL?
L3 22 S L1 AND L2
L4 4954 S (HMG-COA REDUCT?)

=> s l2 and l4
L5 4 L2 AND L4

=> d 1-4

L5 ANSWER 1 OF 4 MEDLINE on STN

Full Text

AN 2006407807 MEDLINE
DN PubMed ID: 16685502
TI Effects of statins on the adipocyte maturation and expression of glucose
transporter 4 (SLC2A4): implications in glycaemic control.
AU Nakata M; Nagasaka S; Kusaka I; Matsuoka H; Ishibashi S; Yada T
CS Department of Physiology, Division of Integrative Physiology, Jichi
Medical University, School of Medicine, Shimotsuke, Tochigi 329-0498,
Japan.
SO Diabetologia, (2006 Aug) Vol. 49, No. 8, pp. 1881-92. Electronic
Publication: 2006-05-10.
Journal code: 0006777. ISSN: 0012-186X.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200610
ED Entered STN: 11 Jul 2006
Last Updated on STN: 25 Oct 2006
Entered Medline: 24 Oct 2006

L5 ANSWER 2 OF 4 MEDLINE on STN

Full Text

AN 2005625619 MEDLINE
DN PubMed ID: 16306567
TI Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on
lipid and glucose metabolism in patients with type 2 diabetes.
AU Kawai Toshihide; Tokui Mikiya; Funae Osamu; Meguro Shu; Yamada Satoru;
Tabata Mitsuhisa; Shimada Akira
CS Department of Internal Medicine, School of Medicine, Keio University, 35
Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan..
tkawai@sc.itc.keio.ac.jp

SO Diabetes care, (2005 Dec) Vol. 28, No. 12, pp. 2980-1.
 Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT (CONTROLLED CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (CLINICAL TRIAL)
 LA English
 FS Priority Journals
 EM 200601
 ED Entered STN: 29 Nov 2005
 Last Updated on STN: 1 Feb 2006
 Entered Medline: 31 Jan 2006

L5 ANSWER 3 OF 4 MEDLINE on STN

Full Text

AN 2005296117 MEDLINE
 DN PubMed ID: 15942117
 TI Effects of atorvastatin on glucose metabolism and insulin resistance
 in KK/Ay mice.
 AU Suzuki Masatsune; Kakuta Hirotooshi; Takahashi Akimitsu; Shimano Hitoshi;
 Tada-Iida Kaoruko; Yokoo Tomotaka; Kihara Rumi; Yamada Nobuhiro
 CS Department of Internal Medicine, Institute of Clinical Medicine,
 University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
 SO Journal of atherosclerosis and thrombosis, (2005) Vol. 12, No. 2, pp.
 77-84.
 Journal code: 9506298. ISSN: 1340-3478.
 CY Japan
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200509
 ED Entered STN: 9 Jun 2005
 Last Updated on STN: 14 Sep 2005
 Entered Medline: 13 Sep 2005

L5 ANSWER 4 OF 4 MEDLINE on STN

Full Text

AN 2004481909 MEDLINE
 DN PubMed ID: 15449970
 TI Impaired glucose metabolism in patients with heart failure:
 pathophysiology and possible treatment strategies.
 AU Tenenbaum Alexander; Fisman Enrique Z
 CS Cardiac Rehabilitation Institute, Sheba Medical Center, Tel-Hashomer,
 Israel.
 SO American journal of cardiovascular drugs : drugs, devices, and other
 interventions, (2004) Vol. 4, No. 5, pp. 269-80. Ref: 156
 Journal code: 100967755. ISSN: 1175-3277.
 CY New Zealand
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200411
 ED Entered STN: 29 Sep 2004
 Last Updated on STN: 19 Dec 2004
 Entered Medline: 26 Nov 2004

=> s (pravastatin or lovastatin or simvastatin or fluvastatin or cerivastatin or atorvastatin
 2865 PRAVASTATIN
 4097 LOVASTATIN
 0 SIMNASTATIN
 1091 FLUVASTATIN
 600 CERIVASTATIN
 2693 ATORVASTATIN
 154 PITAVASTATIN
 497 ROSUVASTATIN
 L6 9724 (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR
 CERIVASTATIN OR ATORVASTATIN OR PITAVASTATIN OR ROSUVASTATIN)

=> d his

(FILE 'HOME' ENTERED AT 00:08:48 ON 03 AUG 2007)

FILE 'MEDLINE' ENTERED AT 00:09:21 ON 03 AUG 2007

L1 10934 S STATIN?
L2 16662 S GLUCOSE METABOL?
L3 22 S L1 AND L2
L4 4954 S (HMG-COA REDUCT?)
L5 4 S L2 AND L4
L6 9724 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C

=> s l2 and l6

L7 11 L2 AND L6

=> d 1-11

L7 ANSWER 1 OF 11 MEDLINE on STN

Full Text

AN 2006413066 MEDLINE
DN PubMed ID: 16835466
TI Statins: beneficial or adverse for **glucose metabolism**.
AU Sasaki Jun; Iwashita Mikio; Kono Suminori
CS Graduate School of Clinical Trial Management, International University of Health and Welfare, Fukuoka, Japan.. jsas@nifty.com
SO Journal of atherosclerosis and thrombosis, (2006 Jun) Vol. 13, No. 3, pp. 123-9. Ref: 37
Journal code: 9506298. ISSN: 1340-3478.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200609
ED Entered STN: 13 Jul 2006
Last Updated on STN: 29 Sep 2006
Entered Medline: 28 Sep 2006

L7 ANSWER 2 OF 11 MEDLINE on STN

Full Text

AN 2006407807 MEDLINE
DN PubMed ID: 16685502
TI Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
AU Nakata M; Nagasaka S; Kusaka I; Matsuoka H; Ishibashi S; Yada T
CS Department of Physiology, Division of Integrative Physiology, Jichi Medical University, School of Medicine, Shimotsuke, Tochigi 329-0498, Japan.
SO Diabetologia, (2006 Aug) Vol. 49, No. 8, pp. 1881-92. Electronic Publication: 2006-05-10.
Journal code: 0006777. ISSN: 0012-186X.
CY Germany; Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200610
ED Entered STN: 11 Jul 2006
Last Updated on STN: 25 Oct 2006
Entered Medline: 24 Oct 2006

L7 ANSWER 3 OF 11 MEDLINE on STN

Full Text

AN 2006369228 MEDLINE
DN PubMed ID: 16784923
TI Effect of **atorvastatin** (10 mg/day) on **glucose metabolism** in patients with the metabolic syndrome.
AU Huptas Sebastian; Geiss Hans-Christian; Otto Carsten; Parhofer Klaus Georg
CS Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.
SO The American journal of cardiology, (2006 Jul 1) Vol. 98, No. 1, pp. 66-9. Electronic Publication: 2006-05-04.

Journal code: 0207277. ISSN: 0002-9149.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(CLINICAL TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200608
ED Entered STN: 21 Jun 2006
Last Updated on STN: 4 Aug 2006
Entered Medline: 3 Aug 2006

L7 ANSWER 4 OF 11 MEDLINE on STN
Full Text
AN 2006097110 MEDLINE
DN PubMed ID: 16484739
TI Effect of **pravastatin** and **atorvastatin** on **glucose metabolism** in
nondiabetic patients with hypercholesterolemia.
AU Ishikawa Michiro; Namiki Atsushi; Kubota Tetsuya; Yajima Suguru; Fukazawa
Masayuki; Moroi Masao; Sugi Kaoru
CS Division of Cardiovascular Medicine, Toho University Ohashi Medical
Center, Tokyo.
SO Internal medicine (Tokyo, Japan), (2006) Vol. 45, No. 2, pp. 51-5.
Electronic Publication: 2006-02-15.
Journal code: 9204241. E-ISSN: 1349-7235.
CY Japan
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200607
ED Entered STN: 18 Feb 2006
Last Updated on STN: 11 Jul 2006
Entered Medline: 10 Jul 2006

L7 ANSWER 5 OF 11 MEDLINE on STN
Full Text
AN 2006008201 MEDLINE
DN PubMed ID: 16394616
TI **Pravastatin** improves insulin resistance in dyslipidemic patients.
AU Okada Kyoko; Maeda Naoyasu; Kikuchi Kensuke; Tatsukawa Masafumi; Sawayama
Yasunori; Hayashi Jun
CS Department of General Medicine, Kyushu University Hospital, Fukuoka,
Japan.. harutani@genmedpr.med.kyushu-u.ac.jp
SO Journal of atherosclerosis and thrombosis, (2005) Vol. 12, No. 6, pp.
322-9.
Journal code: 9506298. ISSN: 1340-3478.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200603
ED Entered STN: 6 Jan 2006
Last Updated on STN: 3 Mar 2006
Entered Medline: 2 Mar 2006

L7 ANSWER 6 OF 11 MEDLINE on STN
Full Text
AN 2005625619 MEDLINE
DN PubMed ID: 16306567
TI Efficacy of **pitavastatin**, a new HMG-CoA reductase inhibitor, on lipid
and **glucose metabolism** in patients with type 2 diabetes.
AU Kawai Toshihide; Tokui Mikiya; Funae Osamu; Meguro Shu; Yamada Satoru;
Tabata Mitsuhisa; Shimada Akira
CS Department of Internal Medicine, School of Medicine, Keio University, 35
Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan..
tkawai@sc.itc.keio.ac.jp
SO Diabetes care, (2005 Dec) Vol. 28, No. 12, pp. 2980-1.
Journal code: 7805975. ISSN: 0149-5992.
CY United States
DT (CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)

(CLINICAL TRIAL)

LA English
 FS Priority Journals
 EM 200601
 ED Entered STN: 29 Nov 2005
 Last Updated on STN: 1 Feb 2006
 Entered Medline: 31 Jan 2006

L7 ANSWER 7 OF 11 MEDLINE on STN
Full Text
 AN 2005305974 MEDLINE
 DN PubMed ID: 15953504
 TI Cardiovascular risk: prevention and treatment of the metabolic syndrome.
 AU Tuomilehto Jaakko
 CS University of Helsinki and National Public Health Institute,
 Mannerheimintie 166, Helsinki FIN-00300, Finland..
jaakko.tuomilehto@ktl.fi
 SO Diabetes research and clinical practice, (2005 Jun) Vol. 68 Suppl 2, pp.
 S28-35. Electronic Publication: 2005-04-15. Ref: 30
 Journal code: 8508335. ISSN: 0168-8227.
 CY Ireland
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200510
 ED Entered STN: 15 Jun 2005
 Last Updated on STN: 6 Oct 2005
 Entered Medline: 5 Oct 2005

L7 ANSWER 8 OF 11 MEDLINE on STN
Full Text
 AN 2005296117 MEDLINE
 DN PubMed ID: 15942117
 TI Effects of atorvastatin on glucose metabolism and insulin resistance
 in KK/Ay mice.
 AU Suzuki Masatsune; Kakuta Hirotooshi; Takahashi Akimitsu; Shimano Hitoshi;
 Tada-Iida Kaoruko; Yokoo Tomotaka; Kihara Rumi; Yamada Nobuhiro
 CS Department of Internal Medicine, Institute of Clinical Medicine,
 University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
 SO Journal of atherosclerosis and thrombosis, (2005) Vol. 12, No. 2, pp.
 77-84.
 Journal code: 9506298. ISSN: 1340-3478.
 CY Japan
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200509
 ED Entered STN: 9 Jun 2005
 Last Updated on STN: 14 Sep 2005
 Entered Medline: 13 Sep 2005

L7 ANSWER 9 OF 11 MEDLINE on STN
Full Text
 AN 2005231997 MEDLINE
 DN PubMed ID: 15866088
 TI Statins have additive effects to vertebral bone mineral density in
 combination with risedronate in hypercholesterolemic postmenopausal women.
 AU Tanriverdi Hamit Alper; Barut Aykut; Sarikaya Selda
 CS Menopause Clinic, Department of Obstetrics and Gynecology, Karaelmas
 University Medical School, 67600 Kozlu, Zonguldak, Turkey..
tanriverdi@artemisonline.net
 SO European journal of obstetrics, gynecology, and reproductive biology,
 (2005 May 1) Vol. 120, No. 1, pp. 63-8.
 Journal code: 0375672. ISSN: 0301-2115.
 CY Ireland
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals

EM 200509
ED Entered STN: 4 May 2005
Last Updated on STN: 13 Sep 2005
Entered Medline: 12 Sep 2005

L7 ANSWER 10 OF 11 MEDLINE on STN

Full Text

AN 91284969 MEDLINE
DN PubMed ID: 2060542
TI Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics.
AU Paolisso G; Sgambato S; De Riu S; Gambardella A; Verza M; Varricchio M; D'Onofrio F
CS Istituto di Gerontologia e Geriatria, 1st Medical School, University of Naples, Italy.
SO European journal of clinical pharmacology, (1991) Vol. 40, No. 1, pp. 27-31.
Journal code: 1256165. ISSN: 0031-6970.
CY GERMANY: Germany, Federal Republic of
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 199108
ED Entered STN: 25 Aug 1991
Last Updated on STN: 6 Feb 1998
Entered Medline: 6 Aug 1991

L7 ANSWER 11 OF 11 MEDLINE on STN

Full Text

AN 90042019 MEDLINE
DN PubMed ID: 2681969
TI Endocrine and metabolic abnormalities following kidney transplantation.
AU Horl W H; Riegel W; Wanner C; Haag-Weber M; Schollmeyer P; Wieland H; Wilms H
CS Medizinische Universitätsklinik, Nephrologische Abteilung, Freiburg.
SO Klinische Wochenschrift, (1989 Sep 1) Vol. 67, No. 17, pp. 907-18. Ref: 148
Journal code: 2985205R. ISSN: 0023-2173.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 198912
ED Entered STN: 28 Mar 1990
Last Updated on STN: 28 Mar 1990
Entered Medline: 12 Dec 1989

=> d an ti au so ab kwic 10 11

L7 ANSWER 10 OF 11 MEDLINE on STN

Full Text

AN 91284969 MEDLINE
TI Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics.
AU Paolisso G; Sgambato S; De Riu S; Gambardella A; Verza M; Varricchio M; D'Onofrio F
SO European journal of clinical pharmacology, (1991) Vol. 40, No. 1, pp. 27-31.
Journal code: 1256165. ISSN: 0031-6970.
AB Twelve elderly non-insulin dependent diabetic patients took part in a double-blind, cross-over, randomized study comparing simvastatin 30 mg/day and placebo. Each treatment period lasted 3 weeks and was separated by a 3 week wash-out period. At the end of each treatment period all subjects underwent in randomized order an oral glucose tolerance test (OGTT; 75 g) and an euglycaemic hyperinsulinaemic (50 mU/kg.h) glucose clamp. Simvastatin compared to placebo significantly reduced plasma total cholesterol (7.9 vs 5.3 mmol.l-1), LDL-cholesterol (7.2 vs 4.3 mmol.l-1), triglycerides (2.9 vs 2.1 mmol.l-1), free fatty acids (1106 vs 818 mmol.l-1)

and glucose (7.4 vs 6.6 mmol.l-1) levels. After simvastatin, and in the last 60 min of the glucose clamp, there was an improvement in the action of insulin as demonstrated by stronger inhibition of hepatic glucose output (2.7 vs 5.2 mumol.kg-1.min-1) and stimulation both of the glucose disappearance rate (26.3 vs 19.5 mumol.kg-1.min-1) and **glucose metabolic** clearance rate (4.3 vs 3.6 ml.kg-1.min-1). The changes in glucose turnover parameters were significantly correlated with basal plasma free fatty acids and were independent of plasma glucoregulatory hormones. In conclusion, simvastatin seems to exert beneficial effects both on lipid and **glucose metabolism**.

AB hepatic glucose output (2.7 vs 5.2 mumol.kg-1.min-1) and stimulation both of the glucose disappearance rate (26.3 vs 19.5 mumol.kg-1.min-1) and **glucose metabolic** clearance rate (4.3 vs 3.6 ml.kg-1.min-1). The changes in glucose turnover parameters were significantly correlated with basal plasma free fatty. . . acids and were independent of plasma glucoregulatory hormones. In conclusion, simvastatin seems to exert beneficial effects both on lipid and **glucose metabolism**.

CT
 Diabetes Mellitus, Type 2: DT, drug therapy
 Glucose: ME, metabolism
 Glucose Tolerance Test
 Humans
 *Insulin: PD, pharmacology
 *Lipids: BL, blood
 *Lovastatin: AA, analogs & derivatives
 Lovastatin: PD, pharmacology
 Lovastatin: TU, therapeutic use
 Middle Aged
 Simvastatin
 Triglycerides: BL, blood
 RN 11061-68-0 (Insulin); 50-99-7 (Glucose); 75330-75-5 (Lovastatin); 79902-63-9 (Simvastatin)

L7 ANSWER 11 OF 11 MEDLINE on STN

Full Text

AN 90042019 MEDLINE
 TI Endocrine and metabolic abnormalities following kidney transplantation.
 AU Horl W H; Riegel W; Wanner C; Haag-Weber M; Schollmeyer P; Wieland H; Wilms H
 SO Klinische Wochenschrift, (1989 Sep 1) Vol. 67, No. 17, pp. 907-18. Ref: 148
 Journal code: 2985205R. ISSN: 0023-2173.
 AB Various endocrine and metabolic disturbances associated with long standing uremia persist after kidney transplantation or arise from the use of immunosuppressive drugs. Hyperlipidemia for long time being implicated as the cause of corticosteroids is also observed in renal transplant recipients treated with cyclosporin A monotherapy. After conversion from cyclosporin to azathioprine serum cholesterol and triglyceride concentration fall, and elevation of LDL-cholesterol may also be reversed. There is a tendency for higher HDL-cholesterol in azathioprine and prednisolone treated transplant patients. Those patients who are at risk for clinically significant cholesterol elevations can be predicted by their pretransplant lipid levels, specifically the LDL-fraction. Risk-benefit ratio of conversion and of treatment with lipid-lowering drugs, especially with **lovastatin**, should be carefully examined, also in view of glucose intolerance. Higher incidence of diabetes mellitus requiring insulin therapy in cyclosporin treated transplant recipients has been reported. Cyclosporin may cause toxic effects on pancreatic beta-cells resulting in inhibition of insulin secretion. High doses of cyclosporin induce inhibition of glycogen synthesis in rat liver. Glucose intolerance is reversible after reduction of cyclosporin dose or conversion to azathioprine. Therefore **glucose metabolism** in kidney transplant recipients treated with cyclosporin should be carefully followed. Immunosuppressive therapy may affect reproductive function, arachidonate metabolism and renin-angiotensin-aldosterone system as well as posttransplant calcium and phosphate metabolism. Endocrine and metabolic abnormalities are associated with long standing uremia. After successful kidney transplantation several observations are normalized but further complications arise from the use of immunosuppressive drugs. The present paper reviews various endocrine and metabolic disturbances described following renal transplantation.

AB by their pretransplant lipid levels, specifically the LDL-fraction. Risk-benefit ratio of conversion and of treatment with lipid-lowering drugs, especially with **lovastatin**, should be carefully examined, also in view of glucose intolerance. Higher incidence of diabetes mellitus requiring insulin therapy in cyclosporin. . . . of glycogen synthesis in rat liver. Glucose intolerance is reversible after reduction of cyclosporin dose or conversion to azathioprine. Therefore **glucose metabolism** in kidney transplant recipients treated with cyclosporin should be carefully followed. Immunosuppressive therapy may affect reproductive function, arachidonate metabolism and. . . .

=> file uspatall
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.95	12.16

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 00:17:44 ON 03 AUG 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 00:17:44 ON 03 AUG 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 00:08:48 ON 03 AUG 2007)

FILE 'MEDLINE' ENTERED AT 00:09:21 ON 03 AUG 2007

L1	10934 S STATIN?
L2	16662 S GLUCOSE METABOL?
L3	22 S L1 AND L2
L4	4954 S (HMG-COA REDUCT?)
L5	4 S L2 AND L4
L6	9724 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C
L7	11 S L2 AND L6

FILE 'USPATFULL, USPAT2' ENTERED AT 00:17:44 ON 03 AUG 2007

=> s l1

L8 28460 L1

=> s statin?/cls

'CLS' IS NOT A VALID FIELD CODE

'CLS' IS NOT A VALID FIELD CODE

L9 0 STATIN?/CLS

=> s statin?/clm

L10 1793 STATIN?/CLM

=> s glucose metabol?

L11 4701 GLUCOSE METABOL?

=> s glucose metabol?/clm

L12 273 GLUCOSE METABOL?/CLM

=> s (HMG-CoA reduct?)

L13 7004 (HMG-COA REDUCT?)

=> s (HMG-CoA reduct?)/clm

L14 1163 (HMG-COA REDUCT?)/CLM

=> s (pravastatin or lovastatin or simnastatin or fluvastatin or cerivastatin or atorvastatin
L15 8993 (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR
CERIVASTATIN OR ATORVASTATIN OR PITAVASTATIN OR ROSUVASTATIN)

=> s (pravastatin or lovastatin or simnastatin or fluvastatin or cerivastatin or atorvastatin
L16 1552 (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR
CERIVASTATIN OR ATORVASTATIN OR PITAVASTATIN OR ROSUVASTATIN)/CL

=> s l8 and l11

L17 539 L8 AND L11

=> s 110 and 112
L18 7 L10 AND L12

=> s 111 and 113
L19 383 L11 AND L13

=> s 112 and 114
L20 2 L12 AND L14

=> s 111 an d115
MISSING OPERATOR L11 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s 111 andl 15
MISSING OPERATOR L11 ANDL
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s 111 and 115
L21 533 L11 AND L15

=> s 112 and 116
L22 4 L12 AND L16

=> d 1-4

L22 ANSWER 1 OF 4 USPATFULL on STN

Full Text

AN 2007:24334 USPATFULL
TI Methylnicotinamide derivatives and formulations for treatment of
lipoprotein abnormalities
IN Bender, Robert, Ottawa, CANADA
Chlopicki, Stefan, Krakow, POLAND
Gebicki, Jerzy, Lodz, POLAND
PA Pharmena North America Inc., Ottawa, CANADA (non-U.S. corporation)
PI US 2007021379 A1 20070125
AI US 2006-484892 A1 20060711 (11)
PRAI US 2005-698292P 20050711 (60)
DT Utility
FS APPLICATION
LN.CNT 1716
INCL INCLM: 514/058.000
INCLS: 514/355.000; 514/159.000; 514/423.000; 514/460.000; 514/548.000
NCL NCLM: 514/058.000
NCLS: 514/159.000; 514/355.000; 514/423.000; 514/460.000; 514/548.000
IC IPCI A61K0031-724 [I,A]; A61K0031-716 [I,C*]; A61K0031-60 [I,A];
A61K0031-401 [I,A]; A61K0031-455 [I,A]; A61K0031-366 [I,A];
A61K0031-22 [I,A]; A61K0031-21 [I,C*]
IPCR A61K0031-716 [I,C]; A61K0031-724 [I,A]; A61K0031-21 [I,C];
A61K0031-22 [I,A]; A61K0031-366 [I,C]; A61K0031-366 [I,A];
A61K0031-401 [I,C]; A61K0031-401 [I,A]; A61K0031-455 [I,C];
A61K0031-455 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 2 OF 4 USPATFULL on STN

Full Text

AN 2004:114784 USPATFULL
TI Combinations
IN Allison, Malcolm, Basel, SWITZERLAND
Gatlin, Marjorie Regan, Maplewood, NJ, UNITED STATES
PI US 2004087630 A1 20040506
AI US 2003-362341 A1 20030618 (10)
WO 2001-EP9586 20010820
DT Utility
FS APPLICATION
LN.CNT 684
INCL INCLM: 514/342.000
INCLS: 514/369.000; 514/423.000; 514/460.000; 514/548.000; 514/592.000
NCL NCLM: 514/342.000
NCLS: 514/369.000; 514/423.000; 514/460.000; 514/548.000; 514/592.000
IC [7]

ICM A61K031-4439
 ICS A61K031-426; A61K031-401; A61K031-366; A61K031-225; A61K031-175
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-426
 [ICS,7]; A61K0031-401 [ICS,7]; A61K0031-366 [ICS,7]; A61K0031-225
 [ICS,7]; A61K0031-21 [ICS,7,C*]; A61K0031-175 [ICS,7];
 A61K0031-17 [ICS,7,C*]
 IPCR A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-403 [I,C*];
 A61K0031-405 [I,A]; A61K0031-55 [I,C*]; A61K0031-55 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0001-00 [I,C*];
 A61P0001-04 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A];
 A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
 A61P0005-00 [I,C*]; A61P0005-00 [I,A]; A61P0007-00 [I,C*];
 A61P0007-04 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A];
 A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0013-00 [I,C*];
 A61P0013-00 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A];
 A61P0015-10 [I,A]; A61P0017-00 [I,C*]; A61P0017-00 [I,A];
 A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0027-00 [I,C*];
 A61P0027-02 [I,A]; A61P0027-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 3 OF 4 USPATFULL on STN

Full Text

AN 2003:201442 USPATFULL
 TI Combinations
 IN Cohen, David Saul, New Providence, NJ, UNITED STATES
 PI US 2003139429 A1 20030724
 US 7019010 B2 20060328
 AI US 2002-236651 A1 20020906 (10)
 PRAI US 2001-325485P 20010927 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1304
 INCL INCLM: 514/263.220
 NCL NCLM: 514/263.340; 514/263.220
 IC [7]
 ICM A61K031-522
 IPCI A61K0031-522 [ICM,7]; A61K0031-519 [ICM,7,C*]
 IPCI-2 A61K0031-522 [I,A]; A61K0031-519 [I,C*]
 IPCR A61K0031-425 [I,C*]; A61K0031-425 [I,A]; A61K0031-505 [I,C*];
 A61K0031-505 [I,A]; A61K0031-519 [I,C*]; A61K0031-522 [I,A];
 A61K0031-519 [I,C]; A61K0031-522 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 4 USPATFULL on STN

Full Text

AN 2003:166611 USPATFULL
 TI Combinations
 IN Cohen, David Saul, New Providence, NJ, UNITED STATES
 PI US 2003114469 A1 20030619
 AI US 2002-231427 A1 20020828 (10)
 PRAI US 2001-325485P 20010927 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2636
 INCL INCLM: 514/263.220
 NCL NCLM: 514/263.220
 IC [7]
 ICM A61K031-522
 IPCI A61K0031-522 [ICM,7]; A61K0031-519 [ICM,7,C*]
 IPCR A61K0031-425 [I,C*]; A61K0031-425 [I,A]; A61K0031-505 [I,C*];
 A61K0031-505 [I,A]; A61K0031-519 [I,C*]; A61K0031-522 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d an ti pi kwic 1-4

L22 ANSWER 1 OF 4 USPATFULL on STN

Full Text

AN 2007:24334 USPATFULL
 TI Methylnicotinamide derivatives and formulations for treatment of
 lipoprotein abnormalities
 PI US 2007021379 A1 20070125

CLM What is claimed is:

12. The pharmaceutical composition of claim 1, wherein the statin is mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, pitavastatin, atorvastatin, cerivastatin, rosuvastatin, pentostatin or nystatin, or a pharmaceutically acceptable salt, solvate, clathrate, polymorph, prodrug, or pharmacologically active metabolite thereof.

24. The pharmaceutical composition of claim 13, wherein the statin is mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, pitavastatin, atorvastatin, cerivastatin, rosuvastatin, pentostatin or nystatin, or a pharmaceutically acceptable salt, solvate, clathrate, polymorph, prodrug, or pharmacologically active metabolite thereof.

. . . claim 13, wherein the lipoprotein abnormality is associated with cardiovascular disease, peripheral vascular disease, dyslipidemia, dyslipoproteinemia, restenosis, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, renal disease, inflammation, . . .

54. The method of claims 51, 52 or 53, wherein the statin is mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, pitavastatin, atorvastatin, cerivastatin, rosuvastatin, pentostatin, or nystatin, or a pharmaceutically acceptable salt, solvate, clathrate, polymorph, prodrug, or pharmacologically active metabolite thereof.

L22 ANSWER 2 OF 4 USPATFULL on STN

Full Text

AN 2004:114784 USPATFULL

TI Combinations

PI US 2004087630 A1 20040506

CLM What is claimed is:

4. A composition according to claim 1 wherein the HMG-Co-A reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, pitavastatin, lovastatin, pravastatin, rosuvastatin and simvastatin, or, in each case, a pharmaceutically acceptable salt thereof.

5. A composition according to claim 4 wherein the HMG-Co-A reductase inhibitor is atorvastatin, pitavastatin or fluvastatin, or, in each case, a pharmaceutically acceptable salt thereof.

. . . or treatment of a of disease and disorder selected from the group consisting of hyperglycemia, hyperinsulinaemia, hyperlipidaemia, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, . . .

L22 ANSWER 3 OF 4 USPATFULL on STN

Full Text

AN 2003:201442 USPATFULL

TI Combinations

PI US 2003139429 A1 20030724

US 7019010 B2 20060328

CLM What is claimed is:

5. The pharmaceutical composition of claim 1 wherein the HMG-Co-A reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, pitavastatin, lovastatin, pravastatin, rosuvastatin and simvastatin.

. . . method for the prevention, delay of progression or treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, . . .

L22 ANSWER 4 OF 4 USPATFULL on STN

Full Text

```

AN      2003:166611  USPATFULL
TI      Combinations
PI      US 2003114469      A1  20030619
CLM     What is claimed is:
        5. The pharmaceutical composition of claim 1, wherein the HMG-Co-A
        reductase inhibitor is selected from the group consisting of
        atorvastatin, cerivastatin, fluvastatin, pitavastatin,
        lovastatin, pravastatin, rosuvastatin and simvastatin.

        . . . method for the prevention, delay of progression or treatment of
        sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia,
        hypertriglyceridemia, diabetes, insulin resistance, impaired glucose
        metabolism, conditions of impaired glucose tolerance (IGT), conditions
        of impaired fasting plasma glucose, obesity, diabetic retinopathy,
        diabetic nephropathy, glomerulosclerosis, diabetic neuropathy,. . .

=>
=> d his

        (FILE 'HOME' ENTERED AT 00:08:48 ON 03 AUG 2007)

        FILE 'MEDLINE' ENTERED AT 00:09:21 ON 03 AUG 2007
L1      10934 S STATIN?
L2      16662 S GLUCOSE METABOL?
L3      22 S L1 AND L2
L4      4954 S (HMG-COA REDUCT?)
L5      4 S L2 AND L4
L6      9724 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C
L7      11 S L2 AND L6

        FILE 'USPATFULL, USPAT2' ENTERED AT 00:17:44 ON 03 AUG 2007
L8      28460 S L1
L9      0 S STATIN?/CLS
L10     1793 S STATIN?/CLM
L11     4701 S GLUCOSE METABOL?
L12     273 S GLUCOSE METABOL?/CLM
L13     7004 S (HMG-COA REDUCT?)
L14     1163 S (HMG-COA REDUCT?)/CLM
L15     8993 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C
L16     1552 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C
L17     539 S L8 AND L11
L18     7 S L10 AND L12
L19     383 S L11 AND L13
L20     2 S L12 AND L14
L21     533 S L11 AND L15
L22     4 S L12 AND L16

=> d l20 1-2

L20     ANSWER 1 OF 2  USPATFULL on STN
Full Text
AN      2004:292759  USPATFULL
TI      Glutaminyll based DP IV-inhibitors
IN      Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
        Hoffmann, Matthias, Wengelsdorf, GERMANY, FEDERAL REPUBLIC OF
        Hoffmann, Torsten, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
        Niestroj, Andre J., Sennewitz, GERMANY, FEDERAL REPUBLIC OF
        Schilling, Stephan, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
        Heiser, Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
PI      US 2004229848      A1  20041118
AI      US 2004-839122      A1  20040505 (10)
PRAI    US 2003-467914P      20030505 (60)
        US 2003-468014P      20030505 (60)
DT      Utility
FS      APPLICATION
LN.CNT  16464
INCL    INCLM: 514/114.000
        INCLS: 514/563.000; 514/357.000; 514/408.000; 514/616.000; 546/334.000;
        548/567.000; 562/450.000; 562/015.000; 514/064.000
NCL     NCLM: 514/114.000
        NCLS: 514/064.000; 514/357.000; 514/408.000; 514/563.000; 514/616.000;

```

546/334.000; 548/567.000; 562/015.000; 562/450.000

IC [7]
 ICM C07F009-22
 ICS A61K031-69; A61K031-66
 IPCI C07F0009-22 [ICM,7]; C07F0009-00 [ICM,7,C*]; A61K0031-69 [ICS,7];
 A61K0031-66 [ICS,7]
 IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-4164 [I,C*];
 A61K0031-4178 [I,A]; A61K0031-4184 [I,A]; A61K0031-4188 [I,A];
 A61K0031-4192 [I,C*]; A61K0031-4192 [I,A]; C07D0233-00 [I,C*];
 C07D0233-54 [I,A]; C07F0009-00 [I,C*]; C07F0009-572 [I,A];
 C07F0009-59 [I,A]; C07F0009-6506 [I,A]; C07F0009-6561 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 2004:114784 USPATFULL
 TI Combinations
 IN Allison, Malcolm, Basel, SWITZERLAND
 Gatlin, Marjorie Regan, Maplewood, NJ, UNITED STATES
 PI US 2004087630 A1 20040506
 AI US 2003-362341 A1 20030618 (10)
 WO 2001-EP9586 20010820
 DT Utility
 FS APPLICATION
 LN.CNT 684
 INCL INCLM: 514/342.000
 INCLS: 514/369.000; 514/423.000; 514/460.000; 514/548.000; 514/592.000
 NCL NCLM: 514/342.000
 NCLS: 514/369.000; 514/423.000; 514/460.000; 514/548.000; 514/592.000
 IC [7]
 ICM A61K031-4439
 ICS A61K031-426; A61K031-401; A61K031-366; A61K031-225; A61K031-175
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-426
 [ICS,7]; A61K0031-401 [ICS,7]; A61K0031-366 [ICS,7]; A61K0031-225
 [ICS,7]; A61K0031-21 [ICS,7,C*]; A61K0031-175 [ICS,7];
 A61K0031-17 [ICS,7,C*]
 IPCR A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-403 [I,C*];
 A61K0031-405 [I,A]; A61K0031-55 [I,C*]; A61K0031-55 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0001-00 [I,C*];
 A61P0001-04 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A];
 A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
 A61P0005-00 [I,C*]; A61P0005-00 [I,A]; A61P0007-00 [I,C*];
 A61P0007-04 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A];
 A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0013-00 [I,C*];
 A61P0013-00 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A];
 A61P0015-10 [I,A]; A61P0017-00 [I,C*]; A61P0017-00 [I,A];
 A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0027-00 [I,C*];
 A61P0027-02 [I,A]; A61P0027-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 00:08:48 ON 03 AUG 2007)

FILE 'MEDLINE' ENTERED AT 00:09:21 ON 03 AUG 2007

L1 10934 S STATIN?
 L2 16662 S GLUCOSE METABOL?
 L3 22 S L1 AND L2
 L4 4954 S (HMG-COA REDUCT?)
 L5 4 S L2 AND L4
 L6 9724 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C
 L7 11 S L2 AND L6

FILE 'USPATFULL, USPAT2' ENTERED AT 00:17:44 ON 03 AUG 2007

L8 28460 S L1
 L9 0 S STATIN?/CLS
 L10 1793 S STATIN?/CLM
 L11 4701 S GLUCOSE METABOL?
 L12 273 S GLUCOSE METABOL?/CLM
 L13 7004 S (HMG-COA REDUCT?)
 L14 1163 S (HMG-COA REDUCT?)/CLM

L15 8993 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C
 L16 1552 S (PRAVASTATIN OR LOVASTATIN OR SIMNASTATIN OR FLUVASTATIN OR C
 L17 539 S L8 AND L11
 L18 7 S L10 AND L12
 L19 383 S L11 AND L13
 L20 2 S L12 AND L14
 L21 533 S L11 AND L15
 L22 4 S L12 AND L16

=> d 118 1-7

L18 ANSWER 1 OF 7 USPATFULL on STN

Full Text

AN 2007:24334 USPATFULL
 TI Methylnicotinamide derivatives and formulations for treatment of
 lipoprotein abnormalities
 IN Bender, Robert, Ottawa, CANADA
 Chlopicki, Stefan, Krakow, POLAND
 Gebicki, Jerzy, Lodz, POLAND
 PA Pharmena North America Inc., Ottawa, CANADA (non-U.S. corporation)
 PI US 2007021379 A1 20070125
 AI US 2006-484892 A1 20060711 (11)
 PRAI US 2005-698292P 20050711 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1716
 INCL INCLM: 514/058.000
 INCLS: 514/355.000; 514/159.000; 514/423.000; 514/460.000; 514/548.000
 NCL NCLM: 514/058.000
 NCLS: 514/159.000; 514/355.000; 514/423.000; 514/460.000; 514/548.000
 IC IPCI A61K0031-724 [I,A]; A61K0031-716 [I,C*]; A61K0031-60 [I,A];
 A61K0031-401 [I,A]; A61K0031-455 [I,A]; A61K0031-366 [I,A];
 A61K0031-22 [I,A]; A61K0031-21 [I,C*]
 IPCR A61K0031-716 [I,C]; A61K0031-724 [I,A]; A61K0031-21 [I,C];
 A61K0031-22 [I,A]; A61K0031-366 [I,C]; A61K0031-366 [I,A];
 A61K0031-401 [I,C]; A61K0031-401 [I,A]; A61K0031-455 [I,C];
 A61K0031-455 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 2 OF 7 USPATFULL on STN

Full Text

AN 2006:268587 USPATFULL
 TI Cycloalkyl-Hydroxyl Compounds and Compositions for Cholesterol
 Management and Related Uses
 IN Dasseux, Jean-Louis Henri, Vielle-Toulouse, FRANCE
 Oniciu, Carmen Daniela, Vielle-Toulouse, FRANCE
 PA ESPERION THERAPEUTIC, INC. (non-U.S. corporation)
 PI US 2006229281 A1 20061012
 AI US 2006-426380 A1 20060626 (11)
 RLI Division of Ser. No. US 2003-743287, filed on 23 Dec 2003, PENDING
 PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3314
 INCL INCLM: 514/114.000
 INCLS: 514/301.000; 514/389.000; 514/381.000; 514/378.000; 514/449.000;
 514/460.000; 514/471.000; 514/602.000; 546/114.000; 548/243.000;
 548/253.000; 549/263.000; 549/293.000
 NCL NCLM: 514/114.000
 NCLS: 514/301.000; 514/378.000; 514/381.000; 514/389.000; 514/449.000;
 514/460.000; 514/471.000; 514/602.000; 546/114.000; 548/243.000;
 548/253.000; 549/263.000; 549/293.000
 IC IPCI C07D0498-02 [I,A]; C07D0498-00 [I,C*]; A61K0031-4743 [I,A];
 A61K0031-4738 [I,C*]; A61K0031-42 [I,A]; A61K0031-365 [I,A];
 A61K0031-366 [I,A]
 IPCR C07D0498-00 [I,C]; C07D0498-02 [I,A]; A61K0031-365 [I,C];
 A61K0031-365 [I,A]; A61K0031-366 [I,C]; A61K0031-366 [I,A];
 A61K0031-42 [I,C]; A61K0031-42 [I,A]; A61K0031-4738 [I,C];
 A61K0031-4743 [I,A]; C07C0031-00 [I,C*]; C07C0031-20 [I,A];
 C07C0031-22 [I,A]; C07C0031-24 [I,A]; C07C0059-00 [I,C*];
 C07C0059-11 [I,A]; C07C0059-245 [I,A]; C07C0059-285 [I,A];
 C07C0059-29 [I,A]; C07C0059-46 [I,A]; C07C0059-48 [I,A];

C07C0059-54 [I,A]; C07C0062-00 [I,C*]; C07C0062-02 [I,A];
 C07C0062-06 [I,A]; C07C0065-00 [I,C*]; C07C0065-17 [I,A];
 C07C0069-00 [I,C*]; C07C0069-757 [I,A]; C07D0213-00 [I,C*];
 C07D0213-80 [I,A]; C07D0309-00 [I,C*]; C07D0309-10 [I,A];
 C07D0309-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
 C07F0009-00 [I,C*]; C07F0009-09 [I,A]; C07F0009-117 [I,A];
 C07F0009-24 [I,A]; C07F0009-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 7 USPATFULL on STN

Full Text

AN 2005:138683 USPATFULL
 TI Compositions comprising ether compounds and pharmaceutical uses therefor
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 PA Esperion Therapeutics, Inc. (U.S. corporation)
 PI US 2005119333 A1 20050602
 AI US 2004-990304 A1 20041116 (10)
 RLI Division of Ser. No. US 2002-305440, filed on 26 Nov 2002, GRANTED, Pat.
 No. US 6831105 Division of Ser. No. US 2000-540739, filed on 31 Mar
 2000, GRANTED, Pat. No. US 6506799
 PRAI US 1999-127321P 19990401 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4788
 INCL INCLM: 514/449.000
 INCLS: 514/460.000; 514/473.000
 NCL NCLM: 514/449.000
 NCLS: 514/460.000; 514/473.000
 IC [7]
 ICM A61K031-366
 ICS A61K031-365; A61K031-337
 IPCI A61K0031-366 [ICM,7]; A61K0031-365 [ICS,7]; A61K0031-337 [ICS,7]
 IPCR C07C0043-00 [I,C*]; C07C0043-13 [I,A]; C07C0059-00 [I,C*];
 C07C0059-125 [I,A]; C07C0311-00 [I,C*]; C07C0311-04 [I,A];
 C07D0233-00 [I,C*]; C07D0233-72 [I,A]; C07F0009-00 [I,C*];
 C07F0009-09 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 7 USPATFULL on STN

Full Text

AN 2005:50478 USPATFULL
 TI Hydroxyl compounds and compositions for cholesterol management and
 related uses
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
 PI US 2005043278 A1 20050224
 AI US 2003-743470 A1 20031223 (10)
 PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5724
 INCL INCLM: 514/102.000
 INCLS: 514/449.000; 514/460.000; 514/473.000; 514/553.000; 514/574.000;
 549/510.000; 549/320.000; 558/155.000; 562/041.000; 562/480.000;
 514/570.000
 NCL NCLM: 514/102.000
 NCLS: 514/449.000; 514/460.000; 514/473.000; 514/553.000; 514/570.000;
 514/574.000; 549/320.000; 549/510.000; 558/155.000; 562/041.000;
 562/480.000
 IC [7]
 ICM A61K031-66
 ICS C07D305-12; C07F009-02; A61K031-366; A61K031-365; A61K031-19;
 A61K031-185
 IPCI A61K0031-66 [ICM,7]; C07D0305-12 [ICS,7]; C07D0305-00 [ICS,7,C*];
 C07F0009-02 [ICS,7]; C07F0009-00 [ICS,7,C*]; A61K0031-366
 [ICS,7]; A61K0031-365 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185
 [ICS,7]
 IPCR C07C0031-00 [I,C*]; C07C0031-20 [I,A]; C07C0031-22 [I,A];
 C07C0031-24 [I,A]; C07C0059-00 [I,C*]; C07C0059-11 [I,A];
 C07C0059-245 [I,A]; C07C0059-285 [I,A]; C07C0059-29 [I,A];
 C07C0059-46 [I,A]; C07C0059-48 [I,A]; C07C0059-54 [I,A];
 C07C0062-00 [I,C*]; C07C0062-02 [I,A]; C07C0062-06 [I,A];

C07C0069-00 [I,C*]; C07C0069-757 [I,A]; C07D0213-00 [I,C*];
 C07D0213-80 [I,A]; C07D0309-00 [I,C*]; C07D0309-10 [I,A];
 C07D0309-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
 C07F0009-00 [I,C*]; C07F0009-09 [I,A]; C07F0009-117 [I,A];
 C07F0009-24 [I,A]; C07F0009-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 7 USPATFULL on STN

Full Text

AN 2004:274385 USPATFULL
 TI Dihydroxyl compounds and compositions for cholesterol management and related uses
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
 PI US 2004214887 A1 20041028
 AI US 2003-743109 A1 20031223 (10)
 PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4218
 INCL INCLM: 514/519.000
 INCLS: 514/727.000; 514/730.000; 514/738.000; 558/451.000; 568/704.000;
 568/705.000; 568/715.000
 NCL NCLM: 514/519.000
 NCLS: 514/727.000; 514/730.000; 514/738.000; 558/451.000; 568/704.000;
 568/705.000; 568/715.000
 IC [7]
 ICM A61K031-275
 ICS A61K031-045
 IPCI A61K0031-275 [ICM,7]; A61K0031-045 [ICS,7]
 IPCR C07C0031-00 [I,C*]; C07C0031-20 [I,A]; C07C0031-22 [I,A];
 C07C0031-24 [I,A]; C07C0059-00 [I,C*]; C07C0059-11 [I,A];
 C07C0059-245 [I,A]; C07C0059-285 [I,A]; C07C0059-29 [I,A];
 C07C0059-46 [I,A]; C07C0059-48 [I,A]; C07C0059-54 [I,A];
 C07C0062-00 [I,C*]; C07C0062-02 [I,A]; C07C0062-06 [I,A];
 C07C0069-00 [I,C*]; C07C0069-757 [I,A]; C07D0213-00 [I,C*];
 C07D0213-80 [I,A]; C07D0309-00 [I,C*]; C07D0309-10 [I,A];
 C07D0309-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
 C07F0009-00 [I,C*]; C07F0009-09 [I,A]; C07F0009-117 [I,A];
 C07F0009-24 [I,A]; C07F0009-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 6 OF 7 USPATFULL on STN

Full Text

AN 2004:268304 USPATFULL
 TI Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
 PI US 2004209847 A1 20041021
 US 7119221 B2 20061010
 AI US 2003-743287 A1 20031223 (10)
 PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3569
 INCL INCLM: 514/102.000
 INCLS: 514/460.000; 514/473.000; 514/449.000; 514/553.000; 514/558.000;
 549/292.000; 549/313.000; 549/328.000; 554/220.000; 558/155.000
 NCL NCLM: 560/076.000; 514/102.000
 NCLS: 562/488.000; 514/449.000; 514/460.000; 514/473.000; 514/553.000;
 514/558.000; 549/292.000; 549/313.000; 549/328.000; 554/220.000;
 558/155.000
 IC [7]
 ICM A61K031-66
 ICS A61K031-366; A61K031-365; A61K031-335; A61K031-185
 IPCI A61K0031-66 [ICM,7]; A61K0031-366 [ICS,7]; A61K0031-365 [ICS,7];
 A61K0031-335 [ICS,7]; A61K0031-185 [ICS,7]
 IPCI-2 C07C0063-331 [I,A]; C07C0063-00 [I,C*]; C07C0069-74 [I,A];
 C07C0069-00 [I,C*]
 IPCR C07C0063-00 [I,C]; C07C0063-331 [I,A]; C07C0031-00 [I,C*];
 C07C0031-20 [I,A]; C07C0031-22 [I,A]; C07C0031-24 [I,A];

C07C0059-00 [I,C*]; C07C0059-11 [I,A]; C07C0059-245 [I,A];
 C07C0059-285 [I,A]; C07C0059-29 [I,A]; C07C0059-46 [I,A];
 C07C0059-48 [I,A]; C07C0059-54 [I,A]; C07C0062-00 [I,C*];
 C07C0062-02 [I,A]; C07C0062-06 [I,A]; C07C0065-00 [I,C*];
 C07C0065-17 [I,A]; C07C0069-00 [I,C]; C07C0069-74 [I,A];
 C07C0069-757 [I,A]; C07D0213-00 [I,C*]; C07D0213-80 [I,A];
 C07D0309-00 [I,C*]; C07D0309-10 [I,A]; C07D0309-12 [I,A];
 C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07F0009-00 [I,C*];
 C07F0009-09 [I,A]; C07F0009-117 [I,A]; C07F0009-24 [I,A];
 C07F0009-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 7 OF 7 USPATFULL on STN

Full Text

AN 2004:248171 USPATFULL
 TI Ether compounds and compositions for cholesterol management and related
 uses
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
 PI US 2004192771 A1 20040930
 AI US 2003-743951 A1 20031224 (10)
 RLI Continuation-in-part of Ser. No. US 2001-976867, filed on 11 Oct 2001,
 GRANTED, Pat. No. US 6713507
 DT Utility
 FS APPLICATION
 LN.CNT 6669
 INCL INCLM: 514/526.000
 INCLS: 514/558.000; 554/111.000; 554/113.000
 NCL NCLM: 514/526.000
 NCLS: 514/558.000; 554/111.000; 554/113.000
 IC [7]
 ICM A61K031-275
 ICS A61K031-20
 IPCI A61K0031-275 [ICM,7]; A61K0031-20 [ICS,7]; A61K0031-185
 [ICS,7,C*]
 IPCR A61K0031-185 [I,C*]; A61K0031-20 [I,A]; A61K0031-275 [I,C*];
 A61K0031-275 [I,A]; C07C0043-00 [I,C*]; C07C0043-13 [I,A];
 C07C0043-178 [I,A]; C07C0043-295 [I,A]; C07C0059-00 [I,C*];
 C07C0059-305 [I,A]; C07C0059-60 [I,A]; C07C0059-64 [I,A];
 C07C0059-66 [I,A]; C07C0059-68 [I,A]; C07C0069-00 [I,C*];
 C07C0069-708 [I,A]; C07C0069-712 [I,A]; C07C0261-00 [I,C*];
 C07C0261-04 [I,A]; C07C0309-00 [I,C*]; C07C0309-10 [I,A];
 C07D0233-00 [I,C*]; C07D0233-74 [I,A]; C07D0233-84 [I,A];
 C07D0257-00 [I,C*]; C07D0257-04 [I,A]; C07D0261-00 [I,C*];
 C07D0261-08 [I,A]; C07D0261-12 [I,A]; C07D0305-00 [I,C*];
 C07D0305-12 [I,A]; C07D0307-00 [I,C*]; C07D0307-12 [I,A];
 C07D0307-33 [I,A]; C07D0307-42 [I,A]; C07D0309-00 [I,C*];
 C07D0309-06 [I,A]; C07D0309-30 [I,A]; C07D0309-38 [I,A];
 C07D0309-40 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

31.70

43.86

STN INTERNATIONAL LOGOFF AT 00:23:43 ON 03 AUG 2007

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/Capplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/Capplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/Capplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/Capplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/Capplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 27 JUL 16 Capplus enhanced with French and German abstracts
NEWS 28 JUL 18 CA/Capplus patent coverage enhanced
NEWS 29 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 30 JUL 30 USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:10:22 ON 03 AUG 2007

=> file supatall
'SUPATALL' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file uspatall

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'USPATFULL' ENTERED AT 20:10:51 ON 03 AUG 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:10:51 ON 03 AUG 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s inslin

L1 12 INSLIN

=> s insulin

L2 71293 INSULIN

=> s insulin/clm

L3 10899 INSULIN/CLM

=> s glucose metabol?

L4 4701 GLUCOSE METABOL?

=> s glucose metabol?/clm

L5 273 GLUCOSE METABOL?/CLM

=> s l2 and l4

L6 3467 L2 AND L4

=> s l3 and l5

L7 160 L3 AND L5

=> s 514/3/cls

'CLS' IS NOT A VALID FIELD CODE

'CLS' IS NOT A VALID FIELD CODE

L8 0 514/3/CLS

=> s 514/3/inclm

L9 366 514/3/INCLM

=> s l7 and l9

L10 4 L7 AND L9

=> d 1-4

L10 ANSWER 1 OF 4 USPATFULL on STN

Full Text

AN 2007:184547 USPATFULL

TI Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders

IN Fine, Stuart A., Northbrook, IL, UNITED STATES

Kinsella, Kevin J., La Jolla, CA, UNITED STATES

PA Akesis Pharmaceuticals, La Jolla, CA, UNITED STATES (U.S. corporation)

PI US 2007161540 A1 20070712

AI US 2006-603931 A1 20061122 (11)

RLI Continuation of Ser. No. US 2005-42354, filed on 25 Jan 2005, PENDING
Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED,
Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377,
filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102,
filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549

PRAI US 1999-126489P 19990326 (60)

DT Utility

FS APPLICATION

LN.CNT 2717

INCL INCLM: 514/003.000

INCLS: 514/184.000; 514/594.000; 514/635.000; 514/369.000; 514/568.000

NCL NCLM: 514/003.000

NCLS: 514/184.000; 514/594.000; 514/635.000; 514/369.000; 514/568.000

IC IPCI A61K0038-28 [I,A]; A61K0031-555 [I,A]; A61K0031-426 [I,A];
A61K0031-192 [I,A]; A61K0031-185 [I,C*]; A61K0031-155 [I,A];
A61K0031-17 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 4 USPATFULL on STN

Full Text

AN 2005:268627 USPATFULL
TI Combinations of chromium or vanadium with antidiabetics
IN Fine, Stuart A., Northbrook, IL, UNITED STATES
Kinsella, Kevin J., La Jolla, CA, UNITED STATES
PI US 2005233947 A1 20051020
AI US 2005-88273 A1 20050323 (11)
RLI Continuation of Ser. No. US 2005-42354, filed on 25 Jan 2005, PENDING
Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED,
Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377,
filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102,
filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549
DT Utility
FS APPLICATION
LN.CNT 2752
INCL INCLM: 514/003.000
INCLS: 514/184.000; 514/369.000; 514/592.000; 514/635.000
NCL NCLM: 514/003.000
NCLS: 514/184.000; 514/369.000; 514/592.000; 514/635.000
IC [7]
ICM A61K038-28
ICS A61K031-555; A61K031-426; A61K031-175; A61K031-155
IPCI A61K0038-28 [ICM,7]; A61K0031-555 [ICS,7]; A61K0031-426 [ICS,7];
A61K0031-175 [ICS,7]; A61K0031-17 [ICS,7,C*]; A61K0031-155
[ICS,7]
IPCR A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0031-17 [I,C*];
A61K0031-175 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A];
A61K0031-555 [I,C*]; A61K0031-555 [I,A]; A61K0038-28 [I,C*];
A61K0038-28 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 4 USPATFULL on STN

Full Text

AN 2005:268626 USPATFULL
TI Combinations of chromium or vanadium with antidiabetics for glucose
metabolism disorders
IN Fine, Stuart A., Northbrook, IL, UNITED STATES
Kinsella, Kevin J., La Jolla, CA, UNITED STATES
PI US 2005233946 A1 20051020
AI US 2005-88272 A1 20050323 (11)
RLI Continuation of Ser. No. US 2005-42354, filed on 25 Jan 2005, PENDING
Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED,
Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377,
filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102,
filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549
DT Utility
FS APPLICATION
LN.CNT 2734
INCL INCLM: 514/003.000
INCLS: 514/184.000; 514/369.000; 514/592.000; 514/635.000
NCL NCLM: 514/003.000
NCLS: 514/184.000; 514/369.000; 514/592.000; 514/635.000
IC [7]
ICM A61K038-28
ICS A61K031-555; A61K031-426; A61K031-175; A61K031-155
IPCI A61K0038-28 [ICM,7]; A61K0031-555 [ICS,7]; A61K0031-426 [ICS,7];
A61K0031-175 [ICS,7]; A61K0031-17 [ICS,7,C*]; A61K0031-155
[ICS,7]
IPCR A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0031-17 [I,C*];
A61K0031-175 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A];
A61K0031-555 [I,C*]; A61K0031-555 [I,A]; A61K0038-28 [I,C*];
A61K0038-28 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 4 USPATFULL on STN

Full Text

AN 2005:215468 USPATFULL
TI Combinations of chromium or vanadium with antidiabetics for glucose
metabolism disorders
IN Fine, Stuart A., Northbrook, IL, UNITED STATES
Kinsella, Kevin J., La Jolla, CA, UNITED STATES

PI US 2005187144 A1 20050825
 AI US 2005-42354 A1 20050125 (11)
 RLI Continuation of Ser. No. US 2001-787325, filed on 4 Jun 2001, GRANTED,
 Pat. No. US 6852760 A 371 of International Ser. No. WO 1999-US21377,
 filed on 17 Sep 1999 Continuation-in-part of Ser. No. US 1998-156102,
 filed on 17 Sep 1998, GRANTED, Pat. No. US 6376549
 DT Utility
 FS APPLICATION
 LN.CNT 2744
 INCL INCLM: 514/003.000
 INCLS: 514/184.000; 514/340.000; 514/369.000; 514/592.000; 514/635.000
 NCL NCLM: 514/003.000
 NCLS: 514/184.000; 514/340.000; 514/369.000; 514/592.000; 514/635.000
 IC [7]
 ICM A61K038-28
 ICS A61K031-555; A61K031-426; A61K031-4439; A61K031-175; A61K031-155
 IPCI A61K0038-28 [ICM,7]; A61K0031-555 [ICS,7]; A61K0031-426 [ICS,7];
 A61K0031-4439 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-175
 [ICS,7]; A61K0031-17 [ICS,7,C*]; A61K0031-155 [ICS,7]
 IPCR A61K0033-24 [I,C*]; A61K0033-24 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s (HMG-CoA reducta? or statin?)
 L11 32857 (HMG-COA REDUCTA? OR STATIN?)

=> s (HMG-CoA reducta? or statin?) /clm
 L12 2798 (HMG-COA REDUCTA? OR STATIN?)

=> d his

(FILE 'HOME' ENTERED AT 20:10:22 ON 03 AUG 2007)

FILE 'USPATFULL, USPAT2' ENTERED AT 20:10:51 ON 03 AUG 2007

L1 12 S INSLIN
 L2 71293 S INSULIN
 L3 10899 S INSULIN/CLM
 L4 4701 S GLUCOSE METABOL?
 L5 273 S GLUCOSE METABOL?/CLM
 L6 3467 S L2 AND L4
 L7 160 S L3 AND L5
 L8 0 S 514/3/CLS
 L9 366 S 514/3/INCLM
 L10 4 S L7 AND L9
 L11 32857 S (HMG-COA REDUCTA? OR STATIN?)
 L12 2798 S (HMG-COA REDUCTA? OR STATIN?) /CLM

=> s l2 and l11
 L13 5192 L2 AND L11

=> s l3 and l12
 L14 522 L3 AND L12

=> s l4 and l13
 L15 626 L4 AND L13

=> s l5 and l14
 L16 7 L5 AND L14

=> d 1-7

L16 ANSWER 1 OF 7 USPATFULL on STN

Full Text

AN 2007:24334 USPATFULL
 TI Methylnicotinamide derivatives and formulations for treatment of
 lipoprotein abnormalities
 IN Bender, Robert, Ottawa, CANADA
 Chlopicki, Stefan, Krakow, POLAND
 Gebicki, Jerzy, Lodz, POLAND
 PA Pharmena North America Inc., Ottawa, CANADA (non-U.S. corporation)
 PI US 2007021379 A1 20070125
 AI US 2006-484892 A1 20060711 (11)

PRAI US 2005-698292P 20050711 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1716
 INCL INCLM: 514/058.000
 INCLS: 514/355.000; 514/159.000; 514/423.000; 514/460.000; 514/548.000
 NCL NCLM: 514/058.000
 NCLS: 514/159.000; 514/355.000; 514/423.000; 514/460.000; 514/548.000
 IC IPCI A61K0031-724 [I,A]; A61K0031-716 [I,C*]; A61K0031-60 [I,A];
 A61K0031-401 [I,A]; A61K0031-455 [I,A]; A61K0031-366 [I,A];
 A61K0031-22 [I,A]; A61K0031-21 [I,C*]
 IPCR A61K0031-716 [I,C]; A61K0031-724 [I,A]; A61K0031-21 [I,C];
 A61K0031-22 [I,A]; A61K0031-366 [I,C]; A61K0031-366 [I,A];
 A61K0031-401 [I,C]; A61K0031-401 [I,A]; A61K0031-455 [I,C];
 A61K0031-455 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 2 OF 7 USPATFULL on STN

Full Text

AN 2006:268587 USPATFULL
 TI Cycloalkyl-Hydroxyl Compounds and Compositions for Cholesterol
 Management and Related Uses
 IN Dasseux, Jean-Louis Henri, Vielle-Toulouse, FRANCE
 Oniciu, Carmen Daniela, Vielle-Toulouse, FRANCE
 PA ESPERION THERAPEUTIC, INC. (non-U.S. corporation)
 PI US 2006229281 A1 20061012
 AI US 2006-426380 A1 20060626 (11)
 RLI Division of Ser. No. US 2003-743287, filed on 23 Dec 2003, PENDING
 PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3314
 INCL INCLM: 514/114.000
 INCLS: 514/301.000; 514/389.000; 514/381.000; 514/378.000; 514/449.000;
 514/460.000; 514/471.000; 514/602.000; 546/114.000; 548/243.000;
 548/253.000; 549/263.000; 549/293.000
 NCL NCLM: 514/114.000
 NCLS: 514/301.000; 514/378.000; 514/381.000; 514/389.000; 514/449.000;
 514/460.000; 514/471.000; 514/602.000; 546/114.000; 548/243.000;
 548/253.000; 549/263.000; 549/293.000
 IC IPCI C07D0498-02 [I,A]; C07D0498-00 [I,C*]; A61K0031-4743 [I,A];
 A61K0031-4738 [I,C*]; A61K0031-42 [I,A]; A61K0031-365 [I,A];
 A61K0031-366 [I,A]
 IPCR C07D0498-00 [I,C]; C07D0498-02 [I,A]; A61K0031-365 [I,C];
 A61K0031-365 [I,A]; A61K0031-366 [I,C]; A61K0031-366 [I,A];
 A61K0031-42 [I,C]; A61K0031-42 [I,A]; A61K0031-4738 [I,C];
 A61K0031-4743 [I,A]; C07C0031-00 [I,C*]; C07C0031-20 [I,A];
 C07C0031-22 [I,A]; C07C0031-24 [I,A]; C07C0059-00 [I,C*];
 C07C0059-11 [I,A]; C07C0059-245 [I,A]; C07C0059-285 [I,A];
 C07C0059-29 [I,A]; C07C0059-46 [I,A]; C07C0059-48 [I,A];
 C07C0059-54 [I,A]; C07C0062-00 [I,C*]; C07C0062-02 [I,A];
 C07C0062-06 [I,A]; C07C0065-00 [I,C*]; C07C0065-17 [I,A];
 C07C0069-00 [I,C*]; C07C0069-757 [I,A]; C07D0213-00 [I,C*];
 C07D0213-80 [I,A]; C07D0309-00 [I,C*]; C07D0309-10 [I,A];
 C07D0309-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
 C07F0009-00 [I,C*]; C07F0009-09 [I,A]; C07F0009-117 [I,A];
 C07F0009-24 [I,A]; C07F0009-44 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 7 USPATFULL on STN

Full Text

AN 2005:50478 USPATFULL
 TI Hydroxyl compounds and compositions for cholesterol management and
 related uses
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
 PI US 2005043278 A1 20050224
 AI US 2003-743470 A1 20031223 (10)
 PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5724

INCL INCLM: 514/102.000
 INCLS: 514/449.000; 514/460.000; 514/473.000; 514/553.000; 514/574.000;
 549/510.000; 549/320.000; 558/155.000; 562/041.000; 562/480.000;
 514/570.000

NCL NCLM: 514/102.000
 NCLS: 514/449.000; 514/460.000; 514/473.000; 514/553.000; 514/570.000;
 514/574.000; 549/320.000; 549/510.000; 558/155.000; 562/041.000;
 562/480.000

IC [7]
 ICM A61K031-66
 ICS C07D305-12; C07F009-02; A61K031-366; A61K031-365; A61K031-19;
 A61K031-185
 IPCI A61K0031-66 [I,C*]; C07D0305-12 [ICS,7]; C07D0305-00 [ICS,7,C*];
 C07F0009-02 [ICS,7]; C07F0009-00 [ICS,7,C*]; A61K0031-366
 [ICS,7]; A61K0031-365 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185
 [ICS,7]
 IPCR C07C0031-00 [I,C*]; C07C0031-20 [I,A]; C07C0031-22 [I,A];
 C07C0031-24 [I,A]; C07C0059-00 [I,C*]; C07C0059-11 [I,A];
 C07C0059-245 [I,A]; C07C0059-285 [I,A]; C07C0059-29 [I,A];
 C07C0059-46 [I,A]; C07C0059-48 [I,A]; C07C0059-54 [I,A];
 C07C0062-00 [I,C*]; C07C0062-02 [I,A]; C07C0062-06 [I,A];
 C07C0069-00 [I,C*]; C07C0069-757 [I,A]; C07D0213-00 [I,C*];
 C07D0213-80 [I,A]; C07D0309-00 [I,C*]; C07D0309-10 [I,A];
 C07D0309-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
 C07F0009-00 [I,C*]; C07F0009-09 [I,A]; C07F0009-117 [I,A];
 C07F0009-24 [I,A]; C07F0009-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 7 USPATFULL on STN

Full Text

AN 2004:292759 USPATFULL
 TI Glutaminyl based DP IV-inhibitors
 IN Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
 Hoffmann, Matthias, Wengelsdorf, GERMANY, FEDERAL REPUBLIC OF
 Hoffmann, Torsten, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
 Niestroj, Andre J., Sennowitz, GERMANY, FEDERAL REPUBLIC OF
 Schilling, Stephan, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
 Heiser, Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF

PI US 2004229848 A1 20041118
 AI US 2004-839122 A1 20040505 (10)
 PRAI US 2003-467914P 20030505 (60)
 US 2003-468014P 20030505 (60)

DT Utility
 FS APPLICATION
 LN.CNT 16464

INCL INCLM: 514/114.000
 INCLS: 514/563.000; 514/357.000; 514/408.000; 514/616.000; 546/334.000;
 548/567.000; 562/450.000; 562/015.000; 514/064.000

NCL NCLM: 514/114.000
 NCLS: 514/064.000; 514/357.000; 514/408.000; 514/563.000; 514/616.000;
 546/334.000; 548/567.000; 562/015.000; 562/450.000

IC [7]
 ICM C07F009-22
 ICS A61K031-69; A61K031-66
 IPCI C07F0009-22 [I,C*]; C07F0009-00 [I,C*]; A61K0031-69 [ICS,7];
 A61K0031-66 [ICS,7]
 IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-4164 [I,C*];
 A61K0031-4178 [I,A]; A61K0031-4184 [I,A]; A61K0031-4188 [I,A];
 A61K0031-4192 [I,C*]; A61K0031-4192 [I,A]; C07D0233-00 [I,C*];
 C07D0233-54 [I,A]; C07F0009-00 [I,C*]; C07F0009-572 [I,A];
 C07F0009-59 [I,A]; C07F0009-6506 [I,A]; C07F0009-6561 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 7 USPATFULL on STN

Full Text

AN 2004:274385 USPATFULL
 TI Dihydroxyl compounds and compositions for cholesterol management and
 related uses
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES

PI US 2004214887 A1 20041028
 AI US 2003-743109 A1 20031223 (10)

PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4218
 INCL INCLM: 514/519.000
 INCLS: 514/727.000; 514/730.000; 514/738.000; 558/451.000; 568/704.000;
 568/705.000; 568/715.000
 NCL NCLM: 514/519.000
 NCLS: 514/727.000; 514/730.000; 514/738.000; 558/451.000; 568/704.000;
 568/705.000; 568/715.000
 IC [7]
 ICM A61K031-275
 ICS A61K031-045
 IPCI A61K0031-275 [ICM,7]; A61K0031-045 [ICS,7]
 IPCR C07C0031-00 [I,C*]; C07C0031-20 [I,A]; C07C0031-22 [I,A];
 C07C0031-24 [I,A]; C07C0059-00 [I,C*]; C07C0059-11 [I,A];
 C07C0059-245 [I,A]; C07C0059-285 [I,A]; C07C0059-29 [I,A];
 C07C0059-46 [I,A]; C07C0059-48 [I,A]; C07C0059-54 [I,A];
 C07C0062-00 [I,C*]; C07C0062-02 [I,A]; C07C0062-06 [I,A];
 C07C0069-00 [I,C*]; C07C0069-757 [I,A]; C07D0213-00 [I,C*];
 C07D0213-80 [I,A]; C07D0309-00 [I,C*]; C07D0309-10 [I,A];
 C07D0309-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
 C07F0009-00 [I,C*]; C07F0009-09 [I,A]; C07F0009-117 [I,A];
 C07F0009-24 [I,A]; C07F0009-44 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 7 USPATFULL on STN

Full Text

AN 2004:268304 USPATFULL
 TI Cycloalkyl-hydroxyl compounds and compositions for cholesterol
 management and related uses
 IN Dasseux, Jean-Louis Henri, Brighton, MI, UNITED STATES
 Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
 PI US 2004209847 A1 20041021
 US 7119221 B2 20061010
 AI US 2003-743287 A1 20031223 (10)
 PRAI US 2003-441795P 20030123 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3569
 INCL INCLM: 514/102.000
 INCLS: 514/460.000; 514/473.000; 514/449.000; 514/553.000; 514/558.000;
 549/292.000; 549/313.000; 549/328.000; 554/220.000; 558/155.000
 NCL NCLM: 560/076.000; 514/102.000
 NCLS: 562/488.000; 514/449.000; 514/460.000; 514/473.000; 514/553.000;
 514/558.000; 549/292.000; 549/313.000; 549/328.000; 554/220.000;
 558/155.000
 IC [7]
 ICM A61K031-66
 ICS A61K031-366; A61K031-365; A61K031-335; A61K031-185
 IPCI A61K0031-66 [ICM,7]; A61K0031-366 [ICS,7]; A61K0031-365 [ICS,7];
 A61K0031-335 [ICS,7]; A61K0031-185 [ICS,7]
 IPCI-2 C07C0063-331 [I,A]; C07C0063-00 [I,C*]; C07C0069-74 [I,A];
 C07C0069-00 [I,C*]
 IPCR C07C0063-00 [I,C]; C07C0063-331 [I,A]; C07C0031-00 [I,C*];
 C07C0031-20 [I,A]; C07C0031-22 [I,A]; C07C0031-24 [I,A];
 C07C0059-00 [I,C*]; C07C0059-11 [I,A]; C07C0059-245 [I,A];
 C07C0059-285 [I,A]; C07C0059-29 [I,A]; C07C0059-46 [I,A];
 C07C0059-48 [I,A]; C07C0059-54 [I,A]; C07C0062-00 [I,C*];
 C07C0062-02 [I,A]; C07C0062-06 [I,A]; C07C0065-00 [I,C*];
 C07C0065-17 [I,A]; C07C0069-00 [I,C]; C07C0069-74 [I,A];
 C07C0069-757 [I,A]; C07D0213-00 [I,C*]; C07D0213-80 [I,A];
 C07D0309-00 [I,C*]; C07D0309-10 [I,A]; C07D0309-12 [I,A];
 C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07F0009-00 [I,C*];
 C07F0009-09 [I,A]; C07F0009-117 [I,A]; C07F0009-24 [I,A];
 C07F0009-44 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 7 USPATFULL on STN

Full Text

AN 2004:114784 USPATFULL
 TI Combinations

IN Allison, Malcolm, Basel, SWITZERLAND
 Gatlin, Marjorie Regan, Maplewood, NJ, UNITED STATES
 PI US 2004087630 A1 20040506
 AI US 2003-362341 A1 20030618 (10)
 WO 2001-EP9586 20010820
 DT Utility
 FS APPLICATION
 LN.CNT 684
 INCL INCLM: 514/342.000
 INCLS: 514/369.000; 514/423.000; 514/460.000; 514/548.000; 514/592.000
 NCL NCLM: 514/342.000
 NCLS: 514/369.000; 514/423.000; 514/460.000; 514/548.000; 514/592.000
 IC [7]
 ICM A61K031-4439
 ICS A61K031-426; A61K031-401; A61K031-366; A61K031-225; A61K031-175
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-426
 [ICS,7]; A61K0031-401 [ICS,7]; A61K0031-366 [ICS,7]; A61K0031-225
 [ICS,7]; A61K0031-21 [ICS,7,C*]; A61K0031-175 [ICS,7];
 A61K0031-17 [ICS,7,C*]
 IPCR A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-403 [I,C*];
 A61K0031-405 [I,A]; A61K0031-55 [I,C*]; A61K0031-55 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0001-00 [I,C*];
 A61P0001-04 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A];
 A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
 A61P0005-00 [I,C*]; A61P0005-00 [I,A]; A61P0007-00 [I,C*];
 A61P0007-04 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A];
 A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0013-00 [I,C*];
 A61P0013-00 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A];
 A61P0015-10 [I,A]; A61P0017-00 [I,C*]; A61P0017-00 [I,A];
 A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0027-00 [I,C*];
 A61P0027-02 [I,A]; A61P0027-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s blood sugar?

L17 7873 BLOOD SUGAR?

=> s blood sugar?/clm

L18 609 BLOOD SUGAR?/CLM

=> d his

(FILE 'HOME' ENTERED AT 20:10:22 ON 03 AUG 2007)

FILE 'USPATFULL, USPAT2' ENTERED AT 20:10:51 ON 03 AUG 2007

L1 12 S INSLIN
 L2 71293 S INSULIN
 L3 10899 S INSULIN/CLM
 L4 4701 S GLUCOSE METABOL?
 L5 273 S GLUCOSE METABOL?/CLM
 L6 3467 S L2 AND L4
 L7 160 S L3 AND L5
 L8 0 S 514/3/CLS
 L9 366 S 514/3/INCLM
 L10 4 S L7 AND L9
 L11 32857 S (HMG-COA REDUCTA? OR STATIN?)
 L12 2798 S (HMG-COA REDUCTA? OR STATIN?) /CLM
 L13 5192 S L2 AND L11
 L14 522 S L3 AND L12
 L15 626 S L4 AND L13
 L16 7 S L5 AND L14
 L17 7873 S BLOOD SUGAR?
 L18 609 S BLOOD SUGAR?/CLM

=> s l3 and l18

L19 151 L3 AND L18

=> s l9 and l19

L20 9 L9 AND L19

=> d 1-9

L20 ANSWER 1 OF 9 USPATFULL on STN

Full Text

AN 2005:281479 USPATFULL
TI Materials and methods for modulating metabolism
IN Chan, Bill Piu, Beijing, CHINA
Wong, Gary Kwan Po, Kowloon, HONG KONG
Xu, Jinxian, Shanghai, CHINA
Chi, Francis, Kowloon, HONG KONG
PI US 2005245433 A1 20051103
AI US 2005-118737 A1 20050429 (11)
PRAI US 2004-567899P 20040503 (60)
US 2004-637618P 20041220 (60)
DT Utility
FS APPLICATION
LN.CNT 1729
INCL INCLM: 514/003.000
INCLS: 514/665.000; 514/340.000; 514/369.000; 514/563.000; 514/025.000
NCL NCLM: 514/003.000
NCLS: 514/025.000; 514/340.000; 514/369.000; 514/563.000; 514/665.000
IC [7]
ICM A61K038-28
ICS A61K031-4439; A61K031-426; A61K031-13
IPCI A61K0038-28 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-4427
[ICS,7,C*]; A61K0031-426 [ICS,7]; A61K0031-13 [ICS,7]
IPCR A61K0031-13 [I,C*]; A61K0031-13 [I,A]; A61K0031-426 [I,C*];
A61K0031-426 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
A61K0038-28 [I,C*]; A61K0038-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 9 USPATFULL on STN

Full Text

AN 2004:233736 USPATFULL
TI Method of food and insulin dose management for a diabetic subject
IN Pilarski, Joseph, Richmond Hill, CANADA
PI US 2004180810 A1 20040916
US 7137951 B2 20061121
AI US 2003-691145 A1 20031022 (10)
PRAI CA 2002-2409374 20021023
US 2002-420289P 20021023 (60)
US 2003-498580P 20030829 (60)
DT Utility
FS APPLICATION
LN.CNT 2517
INCL INCLM: 514/003.000
INCLS: 600/300.000; 705/003.000
NCL NCLM: 600/300.000; 514/003.000
NCLS: 128/922.000; 705/003.000
IC [7]
ICM G06F017-60
ICS A61K038-28; A61B005-00
IPCI G06F0017-60 [ICM,7]; A61K0038-28 [ICS,7]; A61B0005-00 [ICS,7]
IPCI-2 A61B0005-00 [I,A]
IPCR A61B0005-00 [I,C]; A61B0005-00 [I,A]; G06F0019-00 [I,C*];
G06F0019-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 3 OF 9 USPATFULL on STN

Full Text

AN 2002:288070 USPATFULL
TI Method of identification of inhibitors of PDE1C and methods of treatment
of diabetes
IN Michaeli, Tamar H., Bronx, NY, UNITED STATES
PI US 2002160939 A1 20021031
US 6812239 B2 20041102
AI US 2002-85849 A1 20020227 (10)
RLI Continuation of Ser. No. US 1999-245169, filed on 5 Feb 1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 1166
INCL INCLM: 514/003.000
INCLS: 435/004.000; 435/021.000
NCL NCLM: 514/359.000; 514/003.000

NCLS: 514/866.000; 435/004.000; 435/021.000
 IC [7]
 ICM A61K038-28
 ICS C12Q001-42; C12Q001-00
 IPCI A61K0038-28 [ICM,7]; C12Q0001-42 [ICS,7]; C12Q0001-00 [ICS,7]
 IPCI-2 A01N0043-64 [ICM,7]
 IPCR G01N0033-573 [I,C*]; G01N0033-573 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 4 OF 9 USPATFULL on STN

Full Text

AN 2002:266256 USPATFULL
 TI Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey
 IN Schnell, Oliver, Munchen, GERMANY, FEDERAL REPUBLIC OF
 PI US 2002147135 A1 20021010
 AI US 2001-34196 A1 20011220 (10)
 PRAI DE 2000-10064018 20001221
 EP 2000-128168 20001221
 DT Utility
 FS APPLICATION
 LN.CNT 716
 INCL INCLM: 514/003.000
 INCLS: 705/003.000; 705/013.000
 NCL NCLM: 514/003.000
 NCLS: 705/003.000; 705/013.000
 IC [7]
 ICM A61K038-28
 ICS G06F017-60
 IPCI A61K0038-28 [ICM,7]; G06F0017-60 [ICS,7]
 IPCR A61J0007-00 [I,C*]; A61J0007-04 [I,A]; G06F0019-00 [I,C*]; G06F0019-00 [I,A]; G06Q0010-00 [I,C*]; G06Q0010-00 [I,A]

L20 ANSWER 5 OF 9 USPATFULL on STN

Full Text

AN 1999:4626 USPATFULL
 TI Method of treating or preventing type 1 diabetes by oral administration of insulin
 IN Weiner, Howard L., Brookline, MA, United States
 Eisenberth, George, Wellesley, MA, United States
 Hafler, David Allen, West Newton, MA, United States
 Zhang, Zheng, Walden, MA, United States
 PA AutoImmune Inc., Lexington, MA, United States (U.S. corporation)
 PI US 5858968 19990112
 AI US 1995-461585 19950602 (8)
 RLI Continuation of Ser. No. US 1994-235121, filed on 28 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-70020, filed on 28 May 1993, now abandoned which is a continuation of Ser. No. US 1992-896484, filed on 2 Jun 1992, now abandoned which is a continuation of Ser. No. US 1990-595468, filed on 10 Oct 1990, now abandoned
 DT Utility
 FS Granted
 LN.CNT 707
 INCL INCLM: 514/003.000
 INCLS: 424/434.000; 424/435.000
 NCL NCLM: 514/003.000
 NCLS: 424/434.000; 424/435.000
 IC [6]
 ICM A61K038-28
 IPCI A61K0038-28 [ICM,6]
 IPCR A61K0038-10 [N,C*]; A61K0038-11 [N,A]; A61K0038-28 [I,C*]; A61K0038-28 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A]; A61K0039-00 [I,C*]; A61K0039-00 [I,A]
 EXF 514/3; 424/434; 424/435
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 9 USPATFULL on STN

Full Text

AN 1998:150890 USPATFULL
 TI Method of treating or preventing Type 1 diabetes by oral administration of insulin
 IN Weiner, Howard L., Brookline, MA, United States

Eisenbarth, George, Wellesley, MA, United States
 Hafler, David Allen, West Newton, MA, United States
 Zhang, Zhengyi, Walden, MA, United States
 PA Autoimmune, Inc., Lexington, MA, United States (U.S. corporation)
 PI US 5843886 19981201
 AI US 1995-461588 19950602 (8)
 RLI Continuation of Ser. No. US 1994-235121, filed on 28 Apr 1994, now
 abandoned which is a continuation of Ser. No. US 1993-70020, filed on 28
 May 1993, now abandoned which is a continuation of Ser. No. US
 1992-896484, filed on 2 Jun 1992, now abandoned which is a continuation
 of Ser. No. US 1990-595468, filed on 10 Oct 1990, now abandoned
 DT Utility
 FS Granted
 LN.CNT 754
 INCL INCLM: 514/003.000
 INCLS: 424/434.000
 NCL NCLM: 514/003.000
 NCLS: 424/434.000
 IC [6]
 ICM A61K038-28
 IPCI A61K0038-28 [ICM,6]
 IPCR A61K0038-10 [N,C*]; A61K0038-11 [N,A]; A61K0038-28 [I,C*];
 A61K0038-28 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A];
 A61K0039-00 [I,C*]; A61K0039-00 [I,A]
 EXF 514/3; 424/434
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 7 OF 9 USPATFULL on STN

Full Text

AN 1998:65179 USPATFULL
 TI Method of treating or preventing type 1 diabetes by oral administration
 of insulin
 IN Weiner, Howard L., Brookline, MA, United States
 Eisenberth, George, Wellesley, MA, United States
 Hafler, David Allen, West Newton, MA, United States
 Zhang, Zhengyi, Walden, MA, United States
 PA AutoImmune Inc., Lexington, MA, United States (U.S. corporation)
 PI US 5763396 19980609
 AI US 1995-456953 19950601 (8)
 RLI Continuation of Ser. No. US 1994-235121, filed on 28 Apr 1994, now
 abandoned which is a continuation of Ser. No. US 1993-70020, filed on 28
 May 1993, now abandoned which is a continuation of Ser. No. US
 1992-896484, filed on 2 Jun 1992, now abandoned which is a continuation
 of Ser. No. US 1990-595468, filed on 10 Oct 1990, now abandoned
 DT Utility
 FS Granted
 LN.CNT 708
 INCL INCLM: 514/003.000
 INCLS: 514/866.000; 530/303.000; 424/451.000; 424/464.000
 NCL NCLM: 514/003.000
 NCLS: 424/451.000; 424/464.000; 514/866.000; 530/303.000
 IC [6]
 ICM A61K038-28
 IPCI A61K0038-28 [ICM,6]
 IPCR A61K0038-10 [N,C*]; A61K0038-11 [N,A]; A61K0038-28 [I,C*];
 A61K0038-28 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A];
 A61K0039-00 [I,C*]; A61K0039-00 [I,A]
 EXF 514/3; 514/866; 530/303; 424/451; 424/464
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 8 OF 9 USPATFULL on STN

Full Text

AN 97:56634 USPATFULL
 TI Method of treating or preventing type 1 diabetes by oral administration
 of insulin
 IN Weiner, Howard L., Brookline, MA, United States
 Eisenbarth, George, Wellesley, MA, United States
 Hafler, David Allen, West Newton, MA, United States
 Zhang, Zhengyi, Walden, MA, United States
 PA Autoimmune, Inc., Lexington, MA, United States (U.S. corporation)
 PI US 5643868 19970701
 AI US 1995-472016 19950606 (8)

RLI Continuation of Ser. No. US 1994-235121, filed on 28 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-70020, filed on 28 May 1993, now abandoned which is a continuation of Ser. No. US 1992-896484, filed on 2 Jun 1992, now abandoned which is a continuation of Ser. No. US 1990-595468, filed on 10 Oct 1990, now abandoned

DT Utility
FS Granted
LN.CNT 683

INCL INCLM: 514/003.000
INCLS: 530/303.000; 424/184.100

NCL NCLM: 514/003.000
NCLS: 424/184.100; 530/303.000

IC [6]
ICM A61K038-20
ICS A61K039-00; C07K014-62
IPCI A61K0038-20 [ICM,6]; A61K0039-00 [ICS,6]; C07K0014-62 [ICS,6];
C07K0014-435 [ICS,6,C*]
IPCR A61K0038-10 [N,C*]; A61K0038-11 [N,A]; A61K0038-28 [I,C*];
A61K0038-28 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A];
A61K0039-00 [I,C*]; A61K0039-00 [I,A]

EXF 514/3; 530/303; 424/184.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 9 OF 9 USPATFULL on STN

Full Text

AN 95:47704 USPATFULL
TI Method of controlling diabetes mellitus
IN Shohet, Isaac H., 70-34 Kissena Blvd., Flushing, NY, United States
11367

PI US 5420108 19950530
AI US 1992-943176 19920914 (7)

DT Utility
FS Granted
LN.CNT 2806

INCL INCLM: 514/003.000
INCLS: 514/004.000; 514/012.000; 530/300.000; 530/303.000; 530/324.000

NCL NCLM: 514/003.000
NCLS: 514/004.000; 514/012.000; 530/300.000; 530/303.000; 530/324.000

IC [6]
ICM A61K038-28
ICS C07K005-00; C07K007-00; C07K014-62
IPCI A61K0038-28 [ICM,6]; C07K0005-00 [ICS,6]; C07K0007-00 [ICS,6];
C07K0014-62 [ICS,6]; C07K0014-435 [ICS,6,C*]
IPCR A61K0038-28 [I,C*]; A61K0038-28 [I,A]

EXF 514/3; 514/4; 514/12; 530/300; 530/303; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d an ti in pi kwic 1-9

L20 ANSWER 1 OF 9 USPATFULL on STN

Full Text

AN 2005:281479 USPATFULL
TI Materials and methods for modulating metabolism
IN Chan, Bill Piu, Beijing, CHINA
Wong, Gary Kwan Po, Kowloon, HONG KONG
Xu, Jinxian, Shanghai, CHINA
Chi, Francis, Kowloon, HONG KONG

PI US 2005245433 A1 20051103

CLM What is claimed is:

. . . of claim 1, wherein the biological factor is at least one selected from the group consisting of glucose transporter expression; **insulin**-like growth factors; C-peptide levels; blood uric acid levels; microalbumin levels; adiponectin levels; **insulin** levels; glucose levels; **blood sugar** levels; free fatty acid levels; triglyceride levels; high density lipoprotein levels; and low density lipoprotein levels.

. . . of: beta-blockers; benazepril; ramipril; torsemide; alpha-adrenergic blockers; aspirin; ace inhibitors; antiplatelet medications; anticoagulant medications; hypertension medications; antibiotics; H.sub.2-receptor blockers; and **insulin**.

18. The method of claim 17, wherein the other known agents are selected from the group consisting of: **insulin**; sulfonylureas; biguanides; α -glucosidase inhibitors; thiazolidinediones; meglitinides; and D-phenylalanine.

INCL INCLM: 514/003.000

INCLS: 514/665.000; 514/340.000; 514/369.000; 514/563.000; 514/025.000

L20 ANSWER 2 OF 9 USPATFULL on STN

Full Text

AN 2004:233736 USPATFULL

TI Method of food and insulin dose management for a diabetic subject

IN Pilarski, Joseph, Richmond Hill, CANADA

PI US 2004180810 A1 20040916

US 7137951 B2 20061121

CLM What is claimed is:

1. A method of food and **insulin** dose management for a diabetic subject, comprising: c) providing an intended **insulin** unit value or an intended carbohydrate unit value representing the amount of **insulin** or carbohydrate intended for intake by the subject; d) determining the balance value of either **insulin** units or carbohydrate units needed to balance with the provided unit value and maintain **blood sugar** in the subject in a target **blood sugar** range.

3. The method of claim 2, wherein the balance value is calculated by determining for the subject a starting **blood sugar** value and comparing sugar metabolism resulting from the provided unit value with sugar metabolism resulting from the **insulin** units or food units and thereby calculating the amount of **insulin** units or food units necessary to maintain **blood sugar** in the subject in a target **blood sugar** range.

4. The method of claim 3, wherein the sugar metabolism resulting from the provided unit value and sugar metabolism resulting from the **insulin** units or food units are determined individually for a subject from the amount of sugar and rate of release of sugar in food in the subject and the amount of sugar and rate of removal of sugar by **insulin** in the subject.

. . . claim 2 wherein the subject provides an intended food unit value and the method further comprises, a) determining a starting **blood sugar** value in the subject; b) determining from the food unit value i) a total sugar release value and ii) a sugar release rate value; c) determining the balance value by determining an effective amount of **insulin**, **insulin** analog or **insulin** mimetic to administer to the subject to balance with the values in b) so that an ending **blood sugar** value in the subject is in a target **blood sugar** range.

. . . comprising i) the subject receiving food in accordance with the intended standard food unit value and ii) the subject receiving **insulin**, **insulin** analog or **insulin** mimetic containing a number of **insulin** units in accordance with the balance value.

8. The method of claim 2, wherein the subject provides an intended **insulin** unit value and the method further comprises, a) determining a starting **blood sugar** value in the subject; b) determining from the **insulin** unit value i) a total sugar removal value to be removed from the blood of the subject and ii) a . . . food units to be taken in by the subject to balance with the values in b) so that an ending **blood sugar** value in the subject is in a target **blood sugar** range.

9. The method of claim 2, further comprising i) the subject receiving the **insulin**, **insulin** analog or **insulin** mimetic in accordance with the intended **insulin** unit value and ii) the subject receiving food containing a number of food units in accordance with the balance value.

. . . The method of claim 2, wherein i) the subject provides a time schedule for periodic, divided intake of the intended **insulin** unit value or the intended standard food unit value and ii) the balance value is determined according to a time schedule for the subject to intake **insulin** units or food units needed to balance with the provided unit

value and maintain **blood sugar** in the subject in the target **blood sugar** range during the time schedule.

13. The method of claim 2, further comprising determining whether the subject did intake the intended food and **insulin** according to the time schedule and, if the subject did not intake the intended food and **insulin**, then adjusting the ending **blood sugar** value.

14. The method of claim 13, further comprising increasing or decreasing future **insulin** units or food units so that the ending **blood sugar** value is in a target **blood sugar** range.

15. The method of claim 13, wherein if the subject did intake the intended food and **insulin** according to the time schedule and there is over a 25 point difference between the ending **blood sugar** value and the actual **blood sugar** value, then increasing or decreasing future **insulin** units or food units so that the ending **blood sugar** value is in a target **blood sugar** range.

16. The method of claim 6, further comprising repeating steps a)-c), wherein the starting **blood sugar** value in repeated step a) is i) determined by using the ending **blood sugar** level value determined in the prior step c) as the starting **blood sugar** value or ii) determined by measuring a subject **blood sugar**.

17. The method of claim 16 further comprising determining the difference in actual subject **blood sugar** value and ending **blood sugar** values at a plurality of time intervals.

18. The method of claim 6, further comprising: a) entering the starting **blood sugar** value in a timetable b) determining the amount of carbohydrate to be ingested as food units and entering the number. . . and the sugar release rate value per unit of time; d) determining the balance value as the number of balancing **insulin** units to be administered to the subject to balance the total amount of sugar in the carbohydrate units and entering the number of **insulin** units in the timetable; e) determining the total sugar removal value and entering the value in the timetable; f) determining the sugar removal rate value per unit of time after administration of **insulin**, **insulin** analog or **insulin** mimetic and entering the sugar reduction rate value per unit of time in the timetable; f) determining an ending **blood sugar** value for each unit of time and inserting the ending **blood sugar** value as the starting sugar value for the following unit of time.

19. The method of claim 8, further comprising: a) entering the starting **blood sugar** value in a timetable b) determining the amount of **insulin**, **insulin** analog or **insulin** mimetic to be ingested as **insulin** units and entering the number of **insulin** units in the timetable; c) determining the total sugar removal value to be caused by the **insulin** units and the sugar removal rate value per unit of time and entering in the timetable the total sugar removal. . . of balancing food units to be administered to the subject to balance the total amount of sugar removed by the **insulin** units and entering the number of food units in the timetable; e) determining the total sugar release value and entering. . . food units and entering the sugar release rate value per unit of time in the timetable; g) determining an ending **blood sugar** value for each unit of time and inserting the ending **blood sugar** value as the starting sugar value for the following unit of time.

. . . a filed representing units selected from the group consisting of starting sugar, carbohydrate units, sugar release per unit of time, **insulin** units, sugar reduction value per unit of time and ending **blood sugar**.

INCL INCLM: 514/003.000
INCLS: 600/300.000; 705/003.000

L20 ANSWER 3 OF 9 USPATFULL on STN

Full Text

AN 2002:288070 USPATFULL

TI Method of identification of inhibitors of PDE1C and methods of treatment

of diabetes
IN Michaeli, Tamar H., Bronx, NY, UNITED STATES
PI US 2002160939 A1 20021031
US 6812239 B2 20041102

CLM What is claimed is:

1. A method for identifying an agent that increases glucose dependent **insulin** secretion in pancreatic islet β -cells comprising the steps of: (a) obtaining a pancreatic islet β -cell culture; (b) contacting the pancreatic . . . pancreatic islet β -cells, the presence of an inhibitory effect indicating that the agent of interest may be useful for increasing **insulin** secretion.

8. The method of claim 6 wherein said phosphodiesterase 1C inhibitor is administered in an amount effective to regulate **blood sugar** levels in said subject.

INCL INCLM: 514/003.000
INCLS: 435/004.000; 435/021.000

L20 ANSWER 4 OF 9 USPATFULL on STN

Full Text

AN 2002:266256 USPATFULL

TI Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey

IN Schnell, Oliver, Munchen, GERMANY, FEDERAL REPUBLIC OF

PI US 2002147135 A1 20021010

CLM What is claimed is:

4. Method according to claim 3, various travel treatment plans being produced for various types of **insulin** and/or **blood-sugar**-lowering medicines.

8. Method according to claim 4, also comprising recording of the **blood sugar** concentration of the user.

9. Method according to claim 4, also comprising continuous recording of the **blood sugar** concentration by glucose sensors or non-invasive techniques.

11. Method according to claim 4, the various **insulin** types being classified according to their action profile.

12. Method according to claim 4, all **insulin** and/or **blood-sugar**-lowering therapeutics licensed in a starting and/or destination country of a journey being included in the set of travel treatment plans.

13. Method according to claim 12, the set of travel treatment plans being updated in the case of newly licensed **insulin** preparations and/or **blood-sugar**-lowering therapeutics.

22. Method according to claim 1, a travel treatment plan being produced for continuous **blood-sugar**-lowering therapy by means of an **insulin** dosing device.

27. Device according to claim 26, the treatment plan comprising **insulin** doses, **blood-sugar**-lowering therapeutics and/or instructions for the intake of meals.

28. Device according to claim 24, the storage device containing sets of travel treatment plans for all licensed **insulin** types and/or **blood-sugar**-lowering therapeutics licensed in the country of departure and/or destination.

29. Device according to claim 24, the device producing an adapted travel treatment plan for a continuous **blood-sugar**-lowering therapy by means of an **insulin** dosing device.

36. Device according to claim 24, the device being integrated into an apparatus for measuring the **blood sugar** values of a user.

41. Method according to claim 40 for administering **insulin** preparations and/or **blood-sugar**-lowering media.

INCL INCLM: 514/003.000
INCLS: 705/003.000; 705/013.000

L20 ANSWER 5 OF 9 USPATFULL on STN

Full Text

AN 1999:4626 USPATFULL

TI Method of treating or preventing type 1 diabetes by oral administration of insulin

IN Weiner, Howard L., Brookline, MA, United States
Eisenberth, George, Wellesley, MA, United States
Hafler, David Allen, West Newton, MA, United States
Zhang, Zhengi, Walden, MA, United States

PI US 5858968 19990112

CLM What is claimed is:

. . of suppression of said autoimmune reaction comprising administering by inhalation to said mammal an effective amount of a composition comprising **insulin** or a fragment of **insulin** having the property of suppressing said autoimmune reaction, wherein said composition is effective to suppress said autoimmune reaction without an accompanying substantial decrease in the **blood sugar** level of said mammal within four hours after said administration.

4. The method of claim 1 wherein said composition is administered as a saline solution of said **insulin** or fragment.

6. The method of claim 1 wherein said composition comprises **insulin**.

8. A method for treating a mammal suffering from Type 1 diabetes by suppressing autoimmune response associated with said disease, . . . pancreatic beta cell function, the method comprising administering by inhalation to said mammal a composition containing an effective amount of **insulin** or a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without an accompanying substantial decrease in **blood sugar** level of said mammal within four hours after said administration.

10. The method of claim 8 wherein said composition comprises **insulin**.

12. A method for preventing or suppressing the onset of Type 1 diabetes in a mammal by suppressing autoimmune response. . . to said mammal an effective amount for preventing or suppressing the onset of Type 1 diabetes of a composition comprising **insulin** or a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to prevent or suppress said onset without an accompanying substantial decrease in the **blood sugar** level of said mammal within four hours after said administration.

14. The method of claim 12 wherein said composition comprises **insulin**.

15. A method for suppressing autoimmune reaction against pancreatic beta cells in a mammal in need of suppression of said. . . comprising administering by inhalation to said mammal an effective amount of a composition comprising an autoimmune response suppressive analog of **insulin** having at least one antigenic determinant of **insulin** and having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune reaction without an accompanying substantial decrease in the **blood sugar** level of said mammal within four hours after said administration.

18. The method of claim 15 wherein said composition is administered as a saline solution of said **insulin** analog.

. . partial pancreatic beta cell function, the method comprising administering by inhalation to said mammal a composition comprising an analog of **insulin** having at least one antigenic determinant of **insulin** and having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without an accompanying substantial decrease in the **blood sugar** level of said mammal within four hours after said administration.

. . . an effective amount for preventing or suppressing the onset of Type 1 diabetes of a composition comprising an analog of **insulin** having at least one antigenic determinant of **insulin** and having the property of suppressing said autoimmune response, wherein said composition is effective to prevent or suppress said onset without an accompanying substantial decrease in the **blood sugar** level of said mammal within four hours after said administration.

INCL INCLM: 514/003.000
INCLS: 424/434.000; 424/435.000

L20 ANSWER 6 OF 9 USPATFULL on STN

Full Text

AN 1998:150890 USPATFULL

TI Method of treating or preventing Type 1 diabetes by oral administration of insulin

IN Weiner, Howard L., Brookline, MA, United States
Eisenbarth, George, Wellesley, MA, United States
Hafler, David Allen, West Newton, MA, United States
Zhang, Zhengyi, Walden, MA, United States

PI US 5843886 19981201

CLM What is claimed is:

. . . of said autoimmune response, comprising nasally or by mouth administering to said mammal an effective amount of a composition comprising **insulin** or a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without causing a decrease in the **blood sugar** level of said mammal within four hours after said administration.

3. The method of claim 1, wherein said composition comprises **insulin**.

5. A method for treating a mammal suffering from Type 1 diabetes by suppressing an autoimmune response associated with said. . . cell function, the method comprising nasally or by mouth administering to said mammal a composition containing an effective amount of **insulin** or a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without causing a decrease in **blood sugar** level of said mammal within four hours after said administration.

7. The method claim of claim 5, wherein said composition comprises **insulin**.

10. A method for preventing or suppressing the onset of type 1 diabetes in a mammal in need of prevention. . . to said mammal an effective amount for preventing or suppressing the onset of Type 1 diabetes of a composition comprising **insulin** or a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to prevent to suppress said onset without causing a decrease in the **blood sugar** level of said mammal within for hours after said administration.

12. The method of claim 10, wherein said composition comprises **insulin**.

14. A method for suppressing an autoimmune response against pancreatic beta cells in a mammal in need of suppression of. . . or by mouth administering to said mammal an effective amount of a composition comprising an autoimmune response suppressive analog of **insulin** having at least one antigenic determinant of **insulin** and having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without causing a decrease in the **blood sugar** level of said mammal within four hours after said administration.

. . . beta cell function, the method comprising nasally or by mouth administering to said mammal a composition comprising an analog of **insulin** having at least one antigenic determinant of **insulin** and having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without causing a decrease in the **blood sugar** level of said mammal

within four hours after said administration.

- . . . an effective amount for preventing or suppressing the onset of Type 1 diabetes of a composition comprising an analog of **insulin** having at least one antigenic determinant of **insulin** and having the property of suppressing said autoimmune response, wherein said composition is effective to prevent or suppress said onset without an accompanying substantial decrease in the **blood sugar** level of said mammal within four hours after said administration.
- . . . partial pancreatic beta cell function, the method comprising nasally administering to said mammal a composition containing an effective amount of **insulin**, wherein said composition is effective to suppress said autoimmune response without causing a disease in **blood sugar** level of said mammal within four hours after said administration, and wherein said administration continues in single or multiple doses.
- . . . to said mammal an effective amount for preventing or suppressing the onset of Type 1 diabetes of a composition comprising **insulin**, wherein said composition is effective to prevent or suppress said onset without an accompanying substantial decrease in the **blood sugar** level of said mammal within four hours after said administration, said administration continuing in single or multiple doses for at.
- . . . beta cells in a mammal comprising administering nasally or by mouth to said mammal an amount of a fragment of **insulin** effective to suppress said autoimmune response, said fragment being incapable of causing an accompanying decrease in the **blood sugar** level of said mammal.
- . . . beta cells in a mammal comprising administering nasally or by mouth to said mammal an amount of an analog of **insulin** effective to suppress said autoimmune response, said analog being incapable of causing an accompanying decrease in the **blood sugar** level of said mammal.
- . . . the step of administering nasally or by mouth to said individual a composition containing an amount of a fragment of **insulin** effective to suppress an autoimmune response associated with said disease, without causing a decrease in **blood sugar** level of said individual within 4 hours after said administration.
- . . . nasally or by mouth administering to said individual to said individual a composition containing an amount of an analog of **insulin** effective to suppress an autoimmune response associated with said disease, without causing a decrease in **blood sugar** level of said individual within 4 hours after said administration.

32. The method of claim 31 wherein said analog comprises **insulin**.

INCL INCLM: 514/003.000
INCLS: 424/434.000

L20 ANSWER 7 OF 9 USPATFULL on STN

Full Text

AN 1998:65179 USPATFULL
TI Method of treating or preventing type 1 diabetes by oral administration of insulin
IN Weiner, Howard L., Brookline, MA, United States
Eisenberth, George, Wellesley, MA, United States
Hafler, David Allen, West Newton, MA, United States
Zhang, Zhenggi, Walden, MA, United States
PI US 5763396 19980609
CLM What is claimed is:
. . . autoimmune response comprising orally or enterally administering to said mammal an effective amount of a composition comprising a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without causing a decrease in the **blood sugar** level of said mammal within four hours after said administration.
. . . the method comprising orally or enterally administering to said mammal a composition containing an effective amount of a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune

response without causing a decrease in **blood sugar** level of said mammal within four hours after said administration.

. . . an effective amount for preventing or suppressing the onset of Type 1 diabetes of a composition comprising a fragment of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to prevent or suppress said onset without causing a decrease in the **blood sugar** level of said mammal within four hours after said administration.

. . . autoimmune response comprising orally or enterally administering to said mammal an effective amount of a composition comprising an analog of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune reaction without causing a decrease in the **blood sugar** level of said mammal within four hours after said administration.

. . . associated with said disease, the method comprising orally or enterally administering to said mammal a composition comprising an analog of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to suppress said autoimmune response without causing a decrease in the **blood sugar** level of said mammal within four hours after said administration.

. . . an effective amount for preventing or suppressing the onset of Type 1 diabetes of a composition comprising an analog of **insulin** having the property of suppressing said autoimmune response, wherein said composition is effective to prevent or suppress said onset without causing a decrease in the **blood sugar** level of said mammal within four hours after said administration.

. . . pancreatic beta cells in a mammal comprising orally or enterally administering to said mammal an amount of a fragment of **insulin** effective to suppress said autoimmune response, said fragment being incapable of causing an accompanying decrease in the **blood sugar** level of said mammal.

. . . pancreatic beta cells in a mammal comprising orally or enterally administering to said mammal an amount of an analog of **insulin** effective to suppress said autoimmune response, said analog being incapable of causing an accompanying decrease in the **blood sugar** level of said mammal.

. . . comprising the step of orally or enterally administering to said mammal a composition containing an amount of a fragment of **insulin** effective to suppress an autoimmune response associated with said disease, without causing a decrease in **blood sugar** level of said mammal within 4 hours after said administration.

. . . comprising the step of orally or enterally administering to said mammal a composition containing an amount of an analog of **insulin** effective to suppress an autoimmune response associated with said disease, without causing a decrease in **blood sugar** level of said mammal within 4 hours after said administration.

INCL INCLM: 514/003.000
INCLS: 514/866.000; 530/303.000; 424/451.000; 424/464.000

L20 ANSWER 8 OF 9 USPATFULL on STN

Full Text

AN 97:56634 USPATFULL

TI Method of treating or preventing type 1 diabetes by oral administration of insulin

IN Weiner, Howard L., Brookline, MA, United States
Eisenbarth, George, Wellesley, MA, United States
Hafler, David Allen, West Newton, MA, United States
Zhang, Zhengyi, Walden, MA, United States

PI US 5643868 19970701

CLM What is claimed is:

. . . pancreatic beta cells in a mammal comprising orally or enterally administering to said mammal an amount of a composition comprising **insulin** effective to suppress said autoimmune response without causing

a decrease in the **blood sugar** level of said mammal within 4 hours after said administration.

4. The method of claim 1 wherein said composition is orally administered as an aqueous suspension or solution of **insulin**.

7. The method of claim 1 wherein said composition consists of **insulin**.

10. A method for treating a mammal suffering from a disease selected from the group consisting of Type 1 diabetes. . . . Type 1 diabetes comprising the step of orally or enterally administering to said mammal a composition containing an amount of **insulin**, effective to suppress an autoimmune response associated with said disease, without causing a decrease in **blood sugar** level of said mammal within 4 hours after said administration.

. . . 1 diabetes, comprising the step of orally or enterally administering to said mammal an effective amount of a composition comprising **insulin**, prior to said onset and without causing a decrease in the **blood sugar** level of said mammal within 4 hours after said administration.

13. The method of claim 11 wherein said composition consists of **insulin**.

14. A method for suppressing autoimmune reaction against pancreatic beta cells in a patient comprising orally or enterally administering to said patient an effective amount for suppressing said autoimmune reaction of a composition comprising **insulin**, said composition not causing a decrease in the **blood sugar** level of said patient within 4 hours after said administration.

. . . diabetes characterized by an ongoing autoimmune response comprising orally administering to said patient an effective amount of a composition comprising **insulin** that wherein the **insulin** is susceptible to degradation by proteolytic enzymes in the digestive tract, said composition suppressing said ongoing autoimmune response without causing a decrease in the **blood sugar** level of said patient within 4 hours after said administration.

. . . administering to said patient an effective amount for suppressing autoimmune response associated with Type 1 diabetes of a composition comprising **insulin** that wherein the **insulin** is susceptible to degradation by proteolytic enzymes in the digestive tract, said composition not causing a decrease in the **blood sugar** level of said patient within 4 hours after said administration.

17. A method of treating a human patient suffering from a state of Type 1 diabetes characterized by an autoimmune response, comprising oral administration to said patient of a composition comprising **insulin** in amount effective to produce at least one physiological response selected from the group consisting of suppressing said autoimmune response, reducing destruction of beta cells, and eliciting suppressor T-cells that recognize **insulin**, said composition not causing a decrease in the **blood sugar** level of said patient within 4 hours after said administration.

. . . pancreatic beta cells in a mammal comprising orally or enterally administering to said mammal an amount of a composition comprising **insulin** effective to suppress said autoimmune response said composition not causing an accompanying decrease in the **blood sugar** level of said mammal.

INCL INCLM: 514/003.000
INCLS: 530/303.000; 424/184.100

L20 ANSWER 9 OF 9 USPATFULL on STN

Full Text

AN 95:47704 USPATFULL

TI Method of controlling diabetes mellitus

IN Shohet, Isaac H., 70-34 Kissena Blvd., Flushing, NY, United States
11367

PI US 5420108 19950530

CLM What is claimed is:

1. A method for controlling diabetes mellitus in a diabetic patient,

comprising (a) testing both the **blood sugar** level and the urine sugar level of the diabetic patient; (b) administering **insulin** before a meal and sugar after a meal as required by the results of the blood and urine sugar tests; and (c) repeating steps (a) and (b) as needed: wherein the amount of **insulin** and sugar administered is adjusted daily based on the **blood sugar** and urine sugar test results to control diabetes mellitus in the diabetic patient (d) increasing the **insulin** dosage as necessary from the response of the patient to blood and urine sugar content of the patient until a urine sugar level below 2% is reached; and decreasing the **insulin** dosage until a negative urine sugar level content is achieved.

4. A method for controlling diabetes mellitus in a diabetic patient, comprising (a) testing both the **blood sugar** level and the urine sugar level of the diabetic patient seven times a day; (b) administering an amount of **insulin** and sugar supplementation after an initial administration to reach a maximized need, then, in steadily decreasing dosages, decreasing the **insulin** to about one unit less per dose than the amount which would induce **insulin**-induced hypoglycemia; and the sugar supplementation is decreased so as to avoid sugar-induced hyperglycemia; (c) continuing the reduction in sugar and **insulin** dose as needed by results of blood and urine sugar tests until the diabetic patient requires no **insulin** or sugar, and the urine sugar tests will be negative and the **blood sugar** tests will be about normal.

6. A method for reducing or eliminating the dependency of a diabetic patient whose diabetes is out-of-control on administered **insulin**, comprising administering **insulin** to an out-of-control diabetic patient; increasing the **insulin** dosage as necessary from the response of the patient to blood and urine sugar tests to a maximum while monitoring. . . blood and urine sugar content of the patient until a urine sugar level below 2% is reached; and decreasing the **insulin** dosage until a negative urine sugar level content and an **insulin** requirement of zero is achieved; wherein sugar is administered in relation to the **insulin** at dosages in which hypoglycemia is avoided while not causing hyperglycemia.

. . . method of treating a diabetic patient whose diabetes is out-of-control said patient's pancreas being suppressed, exhausted or both comprising administering **insulin** to an out-of-control diabetic patient; increasing the **insulin** dosage as necessary to a maximum that is required by the patient's progress until pancreatic activity is increased as indicated by increased production of **insulin**; and reducing the dosages of administered **insulin** while monitoring the blood and urine sugars as the pancreas function increasingly takes over by steadily increasing its own **insulin** production to meet the needs of the patient.

8. A method of treating a diabetic patient, avoiding the onset of **insulin**-induced hypoglycemia and thereby the damage caused by administering **insulin** to said diabetic patient, said method comprising (a) testing both the **blood sugar** level and the urine sugar level of the diabetic patient; (b) administering **insulin** before a meal and sugar after a meal as required by the results of the blood and urine sugar tests; and (c) repeating steps (a) and (b) as needed: wherein the amount of **insulin** and sugar administered is adjusted daily based on the **blood sugar** and urine sugar test results to avoid the onset of **insulin**-induced hypoglycemia in the diabetic patient (d) increasing the **insulin** dosage as necessary from the response of the patient to blood and urine sugar content of the patient until a urine sugar level below 2% is reached; and decreasing the **insulin** dosage until a negative urine sugar level content is achieved.

9. A method of making diabetes mellitus progressively milder in a diabetic patient, comprising (a) testing both the **blood sugar** level and the urine sugar level of the diabetic patient; (b) administering **insulin** before a meal and sugar after a meal as required by the results of the blood and urine sugar tests; and (c) repeating steps (a) and (b) as needed: and progressively reducing both in **insulin** and sugar administered based on the blood and urine sugar tests as the diabetes is reduced to a progressively milder state; wherein the amount of **insulin** and sugar administered is adjusted daily based on both the

blood sugar and urine sugar test results to make the diabetes mellitus progressively milder (d) increasing the **insulin** dosage as necessary from the response of the patient to blood and urine sugar content of the patient until a urine sugar level below 2% is reached; and decreasing the **insulin** dosage until a negative urine sugar level content is achieved.

10. A method of treating diabetes mellitus to a compensated state in a diabetic patient, comprising (a) testing both the **blood sugar** level and the urine sugar level of the diabetic patient; (b) administering **insulin** before a meal and sugar after a meal as required by the results of the blood and urine sugar tests; and (c) repeating steps (a) and (b) as needed: and wherein the amount of **insulin** and sugar administered is adjusted daily based on both the **blood sugar** and urine sugar test results to treat diabetes mellitus to a compensated state (d) increasing the **insulin** dosage as necessary from the response of the patient to blood and urine sugar content of the patient until a urine sugar level below 2% is reached; and decreasing the **insulin** dosage until a negative urine sugar level content and an **insulin** requirement of zero is achieved.

of treating a diabetic patient, avoiding the onset of iatrogenic hyperinsulinaemia in said diabetic patient, comprising (a) testing both the **blood sugar** level and the urine sugar level of the diabetic patient; (b) administering **insulin** before a meal and sugar after a meal as required by the results of the blood and urine sugar tests; and (c) repeating steps (a) and (b) as needed: wherein the amount of **insulin** and sugar administered is adjusted daily based on both the **blood sugar** and urine sugar test results to avoid the onset of iatrogenic hyperinsulinaemia (d) increasing the **insulin** dosage as necessary from the response of the patient to blood and urine sugar content of the patient until a urine sugar level below 2% is reached; and decreasing the **insulin** dosage until a negative urine sugar level content and an **insulin** requirement of zero is achieved.

12. A method of claim 7, wherein the administration of **insulin**, sugar or both proceeds according to the following:

Test time	Insulin involved
Before breakfast	The evening NPH
2 hours after breakfast	The morning regular
Before lunch	The morning regular
2 hours after lunch	The before.

13. A method of claim 8, wherein the administration of **insulin**, sugar or both proceeds according to the following:

Test time	Insulin involved
Before breakfast	The evening NPH
2 hours after breakfast	The morning regular
Before lunch	The morning regular
2 hours after lunch	The before.

14. A method of claim 9, wherein the administration of **insulin**, sugar or both proceeds according to the following:

Test time	Insulin involved
Before breakfast	The evening NPH
2 hours after breakfast	The morning regular
Before lunch	The morning regular
2 hours after lunch	The before.

15. A method of claim 10, wherein the administration of **insulin**, sugar

or both proceeds according to the following:

Test time	Insulin involved
Before breakfast	
	The evening NPH
2 hours after breakfast	
	The morning regular
Before lunch	The morning regular
2 hours after lunch	
	The before. . .

INCL INCLM: 514/003.000
INCLS: 514/004.000; 514/012.000; 530/300.000; 530/303.000; 530/324.000

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

65.75

65.96

STN INTERNATIONAL LOGOFF AT 20:25:30 ON 03 AUG 2007